Wolters Kluwer

Pediatric Respirology and Critical Care Medicine

SERETIDE® is the only ICS/LABA indicated for asthma control in children of 4 years & above[1-5]

Dose (children 4-11 years)

SERETIDE® Inhaler 50 mcg[1]

TWO inhalations Twice Daily

SERETIDE® Accuhaler® 100 mcg[2]

ONE inhalation Twice Daily

In the BADGER study, patient had better asthma outcomes with Seretide® than if an LTRA was added to a low dose ICS.

- ☑ less exacerbations & treatment failure
- ☑ More symptom-free control days
- ☑ Improvement in lung-function

compared to ICS or LTRA step-up among children uncontrolled on ICS alone[6]

Note to prescribers

- Seretide® should not be used to treat or relief of acute symptoms, for which a short-acting bronchodilator is required
- Patients should not stop treatment abruptly without physician supervision
- Seretide® should be used with caution in patients with pre-existing cardiovascular disease and history of diabetes mellitus
- Systemic effects include Cushing's syndrome, adrenal suppression, growth retardation in children and adolescents, and decrease in bone mineral density. Regular height monitoring is recommended in children receiving prolonged ICS treatment

Adverse effects observed with Seretide® in clinical studies and post-marketing[1,2^]

Frequency Category	Number of Subjects	Description
Very common	≥1/10	Headache*
Common	≥1/100 to <1/10	Muscle cramps, hoarseness/ dysphonia, throat irritation**, headache, candidiasis of mouth and throat and arthralgia
Uncommon	≥1/1000 to <1/100	Rash, cutaneous hypersensitivity, palpitations,and dyspnoea
Rare	≥1/10000 to <1/1000	Angioedema (mainly facial and Oropharyngeal) and bronchospasm

Abbreviated Product Information: INDICATIONS Asthma <u>Accuhaler/Inhaler:</u> Regular treatment of asthma in children & adults, where the use of a bronchodilator plus an inhaled corticosteroid (ICS) is appropriate. **DOSAGE AND ADMINISTRATION** For oral inhalation only. The dose should be titrated to the lowest dose at which effective control of symptoms is maintained. Patients should be given the strength of SERETIDE containing the appropriate fluticasone propionate dosage for the severity of their disease. **Asthma** <u>Accuhaler</u> • Adults & adolescents ≥12 years: 50mcg salmeterol (SALM) & 100mcg, or 250mcg, or 500mcg fluticasone propionate (FP) twice daily. • Children ≥4 years: 50mcg SALM & 100mcg FP twice daily. <u>Inhaler</u> • Adults & adolescents ≥12 years: Two inhalations of 25mcg salmeterol (SALM) & 50mcg, or 125mcg, or 250mcg fluticasone propionate (FP) twice daily. • Children ≥4 years: Two inhalations of 25mcg SALM & 50mcg FP twice daily. **Elderly & patients with renal/hepatic impairment** No need to adjust dose. **CONTRAINDICATIONS** Hypersensitivity to any of the ingredients. **WARNINGS AND PRECAUTIONS** Not for relief of acute symptoms. For patients with COPD cessation of therapy may be associated with symptomatic decompensation and should be supervised by a physician. If the current SERETIDE dosage failed to adequately control asthma, the patient should be reviewed by a physician. Sudden and progressive deterioration in control of asthma is potentially life-threatening and the patient should be reviewed by a physician. Do not stop treatment abruptly. Caution in patients with: thyrotoxicosis; active/quiescent pulmonary tuberculosis; history of diabetes mellitus; pre-existing cardiovascular disease; predisposing low levels of serum potassium. Systemic effects include Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma, for asthma patients the dose of inhaled corticosteroid is titrated to the lowest dose at which effective control is maintained. There was an increased reporting of pneumonia in studies of patients with COPD receiving SERETIDE. Regular height monitoring is recommended in children receiving prolonged ICS treatment. Data from a large US study (SMART) comparing the safety of SALM or placebo added to usual therapy showed a significant increase in asthma-related deaths in patients receiving SALM. SERETIDE Accuhaler contains lactose (which contains milk protein). **INTERACTIONS** Avoid all β-blockers in asthma patients. Concomitant use of FP and ritonavir should be avoided. Care is advised when co-administering potent CYP3A4 inhibitors (e.g. ketoconazole). **PREGNANCY AND LACTATION** Only consider use of drugs during pregnancy & lactation should or if the expected benefit to the mother is greater than any possible risk to the foetus or child. **ADVERSE REACTIONS** Hoarseness/dysphonia; throat irritation; candidiasis of the mouth & throat; palpitations; headache; tremor; muscle cramps; cardiac arrhythmias; cutaneous hypersensitivity reactions; paradoxical bronchospasm; facial & oropharyngeal oedema; contusions. Pneumonia (in COPD patients). **OVERDOSE** If higher than approved doses of SERETIDE are continued over prolonged periods, significant adrenocortical suppression is possible. Please refer to the SERETIDE full prescribing information for warnings, precautions, interactions, pregnancy, lactation, adverse reactions and overdose. Abbreviated PI (GDS 31/IPI17 for Seretide inhalers and GDS24/IPI11-1 for Seretide Accuhalers)

REFERENCES: 1. Seretide® Inhaler (fluticasone propionate/salmeterol) Hong Kong Prescribing Information 2013. **2.** Seretide® Accuhaler® (fluticasone propionate/salmeterol) Hong Kong Prescribing Information 2008. **3.** DeBlic J, et al. Pediatr Allergy Immunol 2009;20:763-771. **4.** IMS Health pharmaceutical data 2010-2015. Assessed on 7 Sept 2015. **5.** Prescribing Information of therapeutics agents indicated for asthma treatment, MIMS Drug Reference (Concise Prescribing Information) Hong Kong. Issue 2, 2015. **6.** Lemanske et al. New Engl. J. Med. 2010; 362(11):975-985.

* Very common adverse event for Seretide Inhaler only. ** Common adverse event for Seretide Accuhaler only.

GlaxoSmithKline Limited
Hong Kong Branch 23/F, Tower 6, The Gateway, 9 Canton Road, Tsimshatsui, Kowloon, Hong Kong. Tel: (852) 3189 8989 Fax: (852) 3189 8931
Macau Branch Avenida Infante D. Henrique No. 43-53A, Edf. Macau Square 21 andar C, Macau. Tel: (853) 2871 5569 Fax: (853) 2871 5987

SERETIDE®
salmeterol/fluticasone propionate

HKRX/SFC/0012/15c (03/2019)
Date of preparation: 21/02/2017

Pediatric Respirology and Critical Care Medicine

Official Journal of Asian Paediatric Pulmonology Society, Hong Kong Society of Paediatric Respirology and Allergy, and Taiwan Society of Pediatric Pulmonology and Critical Care Medicine

General Information

The journal

Pediatric Respirology and Critical Care Medicine is a journal for pediatricians to discuss the latest clinical practice and research in pediatrics and child health. It is the official Journal of Asian Paediatric Pulmonology Society, Hong Kong Society of Paediatric Respirology and Allergy, and Taiwan Society of Pediatric Pulmonology and Critical Care Medicine. The journal's full text is available online at http://www.prccm.org. The journal allows free access (Open Access) to its contents and permits authors to self-archive final accepted version of the articles on any OAI-compliant institutional/subject-based repository.

Abstracting and indexing information

The journal is registered with the following abstracting partners: Baidu Scholar, CNKI (China National Knowledge Infrastructure), EBSCO Publishing's Electronic Databases, Exlibris – Primo Central, Google Scholar, Hinari, Infotrieve, National Science Library, Netherlands ISSN center , ProQuest, TdNet.

Information for authors

The journal does not charge for submission, processing or publication of manuscripts and even for color reproduction of photographs. Please check http://www.prccm.org/contributors.asp for details. All manuscripts must be submitted online at http://www.journalonweb.com/prcm.

Advertising policies

The journal accepts display and classified advertising. Frequency discounts and special positions are available. Inquiries about advertising should be sent to Medknow Publications, advertise@medknow.com. The journal reserves the right to reject any advertisement considered unsuitable according to the set policies of the journal.

The appearance of advertising or product information in the various sections in the journal does not constitute an endorsement or approval by the journal and/or its publisher of the quality or value of the said product or of claims made for it by its manufacturer.

Copyright

Permissions

For information on how to request permissions to reproduce articles/information from this journal, please visit www.prccm.org.

Disclaimer

Addresses

Pediatric Respirology and Critical Care Medicine

Volume 1 ¦ Issue 2 ¦ April-June 2017

Contents

A Joint Effort on Children with Obstructive Apnea by Asian Pediatric Pulmonologists

Obstructive sleep apnea syndrome (OSAS) is a relatively common disease that affects 1%–5% of prepubertal children. While standard management guideline has been developed for the use in developed countries in the USA and Europe, management of childhood OSAS in Asia has not been standardized. In the current issue of *Pediatric Respirology and Critical Care Medicine*, Ng *et al.* published a position statement on behalf of the Asian Paediatric Pulmonology Society (APPS) for management of children with OSAS in Asia based on the expert panel convened by APPS. This up-to-date statement covered the most important issues of OSAS regarding diagnosis, conservative treatment, adenotonsillectomy, orthodontic treatment, and orofacial myofunctional therapy. This report also witnesses the joint effort of pediatric pulmonologists in Asia to achieve a consensus for the care of children with OSAS. I am sure that this position statement provides a useful guide for the primary pediatricians, pediatric pulmonologists, and pediatric sleep specialists.

Nathan reported the findings of a prospective study on the relationship between viral infection in lower respiratory infection and hospitalization for children below 2 years of age who visited the emergency department of a tertiary general hospital in Kuala Lumpur, Malaysia. The authors found that female sex, nursery attendance, and lack of breastfeeding were significantly associated with admissions but not viral infection. The most common viruses identified in the emergency department were respiratory syncytial virus (RSV), human rhinovirus, and parainfluenza virus in the study. This study confirmed the importance of RSV even in tropical climate.

In the review of clinical aspects of pediatrics OSAS, Guilleminault *et al.* reviewed the historical developments of recognition of OSAS. Then, they summarized the physiology of upper airway collapse during sleep. The authors emphasized the variable presenting complaints at different ages of children with OSAS. Accurate diagnosis is the key to successful treatment of OSAS; the level of airway obstruction should be vigilantly looked for. Finally, the pathogenesis of OSA due to orofacial growth at young age, related to the functioning of sucking, swallowing, speech development, and nasal breathing, were emphasized. To decrease morbidity of pediatric patients with obstructive sleep apnea, early recognition and timely treatment remains the goal of therapeutic management.

Kin-Sun Wong

Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan

Address for correspondence: Dr. Kin-Sun Wong,
Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
E-mail: kswong768@gmail.com

How to cite this article: Wong KS. A joint effort on children with obstructive apnea by Asian pediatric pulmonologists. Pediatr Respirol Crit Care Med 2017;1:25.

The Asian Paediatric Pulmonology Society (APPS) Position Statement on Childhood Obstructive Sleep Apnea Syndrome

Daniel Kwok-Keung Ng[1], Yu-Shu Huang[2], Oon-Hoe Teoh[3], Aroonwan Preutthipan[4], Zhi-Fei Xu[5], Takeshi Sugiyama[6], Kin-Sun Wong[7], Ka-Li Kwok[1], Brigitte Kim-Yook Fung[8], Rachel Shui-Ping Lee[1], Jonathan Pak-Heng Ng[1], Shuk-Yu Leung[1], Da-Tian Che[9], Albert Martin Li[10], Tat-Kong Wong[11], Indu Khosla[12], Anna M Nathan[13], Mary Therese M Leopando[14], Hussein Al Kindy[15]

[1]Department of Paediatrics, Kwong Wah Hospital, Hong Kong, [2]Department of Child Psychiatry and Sleep Center, Chang Gung Memorial Hospital and University, Taoyuan, Taiwan, [3]Respiratory Medicine Service, Department of Paediatrics, KK Women's & Children's Hospital, Singapore, [4]Pediatric Pulmonary Division, Department of Pediatrics, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, [5]Department of Respiratory Medicine, Beijing Children's Hospital, Capital Medical University, Beijing, China, [6]Department of Pediatrics, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan, [7]Department of Pediatrics, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan, [8]Physiotherapy Department, Kwong Wah Hospital, Hong Kong, [9]Department of Pulmonary Medicine, Children's Hospital of Shanghai, Jiaotong University School of Medicine, Shanghai, China, [10]Department of Paediatrics, The Chinese University of Hong Kong, Hong Kong, [11]Department of Paediatrics and Adolescent Medicine, University of Hong Kong, [12]Department of Pediatrics, Cloudnine Hospital, Bangalore, India, [13]Department of Paediatrics, University Malaya, Kuala Lumpur, Malaysia, [14]Department of Pediatrics, Philippine Children's Medical Center, Manila, Philippines, [15]Child Health Department, Sultan Qaboos University Hospital, Muscat, Oman

Abstract

With recognition of the importance of obstructive sleep apnea syndrome (OSAS) in children, practice guidelines have been developed for the management of OSAS in the USA and Europe. A panel of experts in pediatric OSAS in Asia were appointed by the Asian Paediatric Pulmonology Society (APPS) to prepare a position statement for management of childhood OSAS in Asia. The purpose of this statement is to provide a reference standard in the diagnosis and management of childhood OSAS for doctors working in Asia. The expert panel determined the scope of this statement. Focused literature search related to the key topics was conducted by panel members. The final content of this statement was agreed on by all panel members and approved by the council of APPS. The current statement covered diagnostic approach, diagnostic criteria, management algorithm, drug-induced sleep endoscopy, medical treatment including medications and positive pressure ventilation, surgical treatment including adenotonsillectomy, orthodontic treatment, and orofacial myofunctional therapy (OMT). Diagnostic criteria of childhood OSAS from 1 year to 18 years were presented that include both clinical (criteria A) and polysomnography findings (criteria B) in the diagnosis of childhood OSAS. The use of nocturnal pulse oximetry as a screening tool was suggested using the McGill oximetry score. Management of OSAS with medical treatment, tonsillectomy and adenoidectomy (TandA), positive airway pressure, orthodontic devices, nasal valves, and OMT were reviewed. Management of persistent OSAS after TandA was addressed, and the importance of weight control was emphasized. The position statement provides a guideline to the management of childhood OSAS in Asia.

Keywords: Child, polysomnography, sleep apnea syndrome, snoring

INTRODUCTION

Obstructive sleep apnea syndrome (OSAS) was reported to affect 1%–6% of prepubertal children.[1,2] While standard management guideline has been developed for use in the developed countries in the USA and Europe, management of childhood OSAS in Asia has not been standardized.[1,3,4] The aim of this position statement is to provide guidance to the management of childhood OSAS in Asian children for general pediatricians and general practitioners. To this aim, a group of experts in pediatric OSAS gathered in 2015 during the 1st Annual Scientific Meeting of the Asian Paediatric Pulmonology Society (APPS) held in Hong Kong in October 2015. A panel was formed and was given the task to prepare the position statement based on the current literature, especially that from Asia and the consensus among the group. The group presented the drafted statement in the International Paediatric Sleep Association in Taiwan in March

How to cite this article: Ng DK, Huang YS, Teoh OH, Preutthipan A, Xu ZF, Sugiyama T, *et al*. The Asian Paediatric Pulmonology Society (APPS) position statement on childhood obstructive sleep apnea syndrome. Pediatr Respirol Crit Care Med 2017;1:26-38.

2016 and comments were received and the group developed the second draft which was presented in the 2nd Annual Scientific Meeting of APPS in Singapore in November 2016. Further comments were received and revision was done. The final draft was presented to the guideline committee of APPS which recommended the statement to be presented to the executive committee of APPS and approval was granted for the statement to be released as the official position statement of APPS in March 2017.

Definition of Obstructive Sleep Apnea Syndrome

The diagnostic criteria of childhood OSAS are defined in Table 1. The current definition does not cover children younger than 1 year old as infants, especially those younger than 3 months, have different types of breathing disorders during sleep.[5]

Risk Factors for Childhood Obstructive Sleep Apnea Syndrome

Adenotonsillar hypertrophy is the most recognized risk factor of OSAS in children.[6,7] Allergic rhinitis and obesity are other common risk factors.[8-12] Other risk factors include well-known structural abnormalities of the airway, such as micrognathia and midfacial hypoplasia, Down syndrome, Prader–Willi syndrome, achondroplasia, and less well-known and subtle defects such as congenital teeth agenesis and septum deviation, short lingual frenulum, and chronic mouth breathing.[13-18] Neuromuscular disorders such as muscular dystrophies, cerebral palsy, and Chiari malformation are at high risk for OSAS. Other factors include gastroesophageal reflux and premature birth.[19-21] Children with a family history of OSAS are at an increased risk for OSAS. Environmental tobacco smoke exposure was also associated with OSAS.[22,23]

Complications of Childhood Obstructive Sleep Apnea Syndrome

Childhood OSAS is associated with neurological and cardiovascular morbidities.[24-29] These neurological morbidities include attention deficit/hyperactivity disorder, hypersomnolence, parasomnia (confusional arousals, sleep terrors, sleep walking, nightmares, and bruxism), depression, aggression, somatization, abnormal social behaviors, and nocturnal enuresis.[30-39] Cardiovascular morbidities include elevated systolic and diastolic blood pressure, dysfunction of autonomic regulation, reduced cerebral blood flow, left ventricular remodeling, and endothelial dysfunction.[25,29,40-46] Childhood OSAS is also associated with growth impairment.[47,48]

Diagnostic Approach

Children of all ages should be screened by their family physicians or pediatricians for the presence of snoring, especially habitual snoring, i.e. 3 or more nights per week and symptoms suggestive of OSAS during routine health checkup [Tables 2 and 3]. If positive, further focused evaluation should be performed.[1]

If there is reported habitual snoring with signs and/or symptoms suggestive of OSAS, further evaluation and management is advised. The approach may vary, depending on the resources available. An algorithm for the evaluation of children with suspected OSAS is suggested in Figure 1.

Sleep polysomnography (PSG), wherever available, is considered the gold standard for diagnosis of OSAS. Attended PSG in the sleep laboratory is preferred, especially for children younger than 4 years old. Several studies demonstrated the validity of unattended study in children but these unattended studies should involve monitoring of electroencephalogram or a way to monitor autonomic nervous system disruption, for example, electrocardiogram + SpO_2 plethysmography.[42,49,50] Nap studies should not be used to substitute these overnight studies.

When PSG, attended or otherwise, is not available, analysis of nocturnal pulse oximetry would provide the second best objective assessment of the child's condition. This monitoring underscores abnormal breathing during sleep as it misses the hypopnea with only arousal. Nocturnal pulse oximetry is a useful diagnostic test only when the OSAS is associated with significant oxygen desaturation. A positive diagnostic test is made when there are 3 or more desaturation clusters (defined as 5 or more desaturations to <90% occurring in a 10–30 min period) [Table 4].[47-49] The positive predictive value and negative predictive value (NPV) of the test were 96.8% and

Table 1: Diagnostic criteria of childhood OSAS (1- to 18-year-old)

Criteria A and B must be met

Criteria A: 1 or more of the followings

Habitual snoring, i.e., ≥3 nights per week

Labored breathing (snorting), or observed obstructive apnea during the child's sleep

Daytime sleepiness, hyperactivity, attention deficit, behavioral problems, learning problems, academic deterioration

Hypertension or nocturnal hypertension

Nocturnal enuresis (primary or secondary)

Excessive sweating during sleep

Chronic NREM parasomnias

Criteria B: PSG demonstrates one or both of the following

One or more obstructive apneas, mixed apneas, or hypopneas, per hour of sleep, i.e., AHI ≥1[#] or

A pattern of obstructive hypoventilation, defined as at least 25% of total sleep time with hypercapnia, i.e., $PaCO_2$ (or validated surrogate marker like $TcCO_2$*) >50 mmHg together with signs of partial obstruction like paradoxical breathing and/or out of phase between chest and abdominal recordings and/or flow limitation

[#]For children older than 12 years, AHI >5 might be used as the cutoff at the discretion of the attending pediatric respirologist, *$TcCO_2$ should be done with a validated transcutaneous CO_2 monitor with *in vivo* calibration by arterial CO_2 or arterialized capillary CO_2. PSG: Polysomnography, NREM: Non rapid eye movement

Figure 1: Management algorithm of children with suspected obstructive sleep apnea syndrome. *High-risk group: age <3 years, obesity, chronic mouth breathing, syndromic or nonsyndromic craniofacial growth disorders, chronic gastroesophageal reflux, chronic upper airway allergies, trisomy 21, cerebral palsy, neuromuscular disorders, chronic lung disease, sickle cell disease, genetic/metabolic diseases. Abbreviations: T and A: Tonsillectomy and adenoidectomy; PAP: Positive airway pressure; RME: Rapid maxillary expansion; MAD: Mandibular advancement device; OMT: Orofacial myofunctional therapy.

58.11%, respectively.[51-53] The major limitation of nocturnal pulse oximetry monitoring is the low NPV when OSAS could not be ruled out.

DRUG-INDUCED SLEEP ENDOSCOPY

Endoscopy has been used to evaluate the upper airway for a long time.[54-56] Good sedation is essential and medications such as midazolam, fentanyl, or propofol are commonly used. As OSAS children are prone to have obstructive apnea/hypopnea with sedation, it is important to have a competent medical practitioner to provide sedation and intervene whenever necessary. Structured reporting format for the findings of endoscopy is important.[57] There are often multilevel obstructions found in patients with sleep-disordered breathing (SDB).[58-62]

Evaluation of four-site "VOTE" was suggested.[63,64] However, this missed out the adenoids in children. Hence, evaluation of six sites was suggested [Figure 2].[65,66]

At the retrolingual level, the degree of hypertrophy of lingual tonsils and features of reflux laryngitis which were commonly associated with obstructive sleep apnea (OSA) should also be noted.[67] Having knowledge of number of sites of obstruction will help to plan management.

MEDICAL TREATMENT OF CHILDHOOD OBSTRUCTIVE SLEEP APNEA SYNDROME

Intranasal corticosteroids

The use of intranasal corticosteroids was shown in a case series by Alexopoulos *et al*. that their use could improve

Table 2: Symptoms of obstructive sleep apnea syndrome

Labored breathing during sleep

Gasps/snorting noises/observed episodes of apnea

Nocturnal enuresis (especially secondary enuresis)

Sleeping in a seated position or with the neck hyperextended

Chronic observed episodic cyanosis during sleep

Headaches on awakening

Daytime sleepiness

Attention-deficit/hyperactivity disorder

Learning problems

Unexplained mood swing

Confusional arousal/sleep walking

Somniloquy

Table 3: Sign of obstructive sleep apnea syndrome

Underweight or overweight

Tonsillar hypertrophy

Adenoidal facies

Micrognathia/retrognathia

High-arched palate

High Mallampati score

Cross or open bite

Increased overjet

Short lingual frenulum

Loud pulmonary component of the second heart sound

Hypertension

PSG findings and OSA symptoms in children with mild SDB.[68]

Later, randomized placebo-controlled trials involving the use of different intranasal corticosteroids, mometasone furoate, budesonide, and fluticasone propionate aqueous spray were shown to decrease apnea-hypopnea index (AHI) [Table 5].[69-71]

A meta-analysis of the above studies conducted by Liu *et al.* in 2016 showed a reduction of AHI by 1.1 with the use of intranasal corticosteroids in children with OSA.[72]

Leukotriene receptor antagonist

Montelukast given for 16 weeks at a dosage of 4 mg/day for <6 years old or 5 mg/day for >6 years old was shown by Goldbart *et al.* in an open-label case–control study involving 46 children aged between 2- and 10-years to be effective in reducing AHI significantly in treatment group, pretreatment 3.0/h to posttreatment 2.0/h, when compared to control group, pretreatment 3.2/h to posttreatment 4.1/h.[73]

Subsequently, Goldbart *et al.* conducted a double–blind, randomized, placebo-controlled trial in children aged between 2- and 10-years that administration of montelukast improved obstructive apnea index (OAI) and AHI significantly.[74]

Kheirandish-Gozal *et al.* published a double-blind, randomized, placebo-controlled trial on the effect of montelukast on OSA children.[75] The study involved 64 OSA children aged between 2- and 10-years and it showed that AHI of treated children

Figure 2: Six important sites recommended for evaluation of obstructive sleep apnea with drug-induced sleep endoscopy.

decreased from 9.2 to 4.2 (*P* < 0.0001) while AHI did not change in those receiving placebo.

A meta-analysis of the above studies was conducted by the authors (DKN, JPN, and SYL) and it showed a reduction of AHI by 2.7 with the use of montelukast [Figure 3].

Combined intranasal corticosteroids and montelukast

Two nonrandomized studies were identified. Kheirandish *et al.* in an open-label control trial (involving 36 children of more than 6 years old) demonstrated that combined use of oral montelukast (4 mg for children <6 years old or 5 mg for children ≥6 years old) and intranasal budesonide (32 mcg/nostril per day) for 12 weeks in postadenotonsillectomy children with residual mild OSA could reduce AHI significantly in treatment group (mean AHI dropped from 3.9 to 0.3) when compared to control group (mean AHI increased from 3.6 to 4.7).[76]

Kheirandish-Gozal *et al.* in a retrospective study showed, involving 836 mild OSA children aged between 2- and 14-years, that the combined use of intranasal corticosteroids and montelukast brought about a significant improvement in AHI.[77]

A meta-analysis of the above studies was conducted by the authors (DKN, JPN, and SYL) and it showed a reduction of AHI by 3.3 with the concurrent use of intranasal corticosteroids and montelukast on OSA children [Figure 4].

TONSILLECTOMY AND ADENOIDECTOMY

Tonsillectomy and adenoidectomy (TandA) is the first-line treatment for children with OSAS with adenotonsillar hypertrophy. The Childhood Adenotonsillectomy Trial (CHAT), a randomized trial of early adenotonsillectomy (eAT) compared to watchful waiting with supportive care (WWSC) for mild-to-moderate childhood OSAS, i.e., AHI ≤5, showed normalization of PSG findings in 79% versus 46% of the respective groups on assessment after 7 months.[78] There were also significantly greater reported reduction in symptoms and improvement in behavior and quality of life in the eAT group than the WWSC group. The significance of the normalization rate of 46% in WWSC group, who nevertheless had worse behavioral performance, warrants further study.[79]

Postoperative complications were reported to be higher in those aged below 3 years, presence of cardiac complications, congenital craniofacial anomalies, neuromuscular disorders, and severe obesity.[80,81] For such high-risk patients, TandA should be performed in facilities with pediatric intensive care

Table 4: The McGill Oximetry Scoring

Score	Comment	Criteria			
		Number of drops in SaO_2 <90%	Number of drops in SaO_2 <85%	Number of drops in SaO_2 <80%	Others
1	Inconclusive for OSA	<3	0	0	Baseline: Stable (<3 clusters of desaturations) and >95%
2	Mild OSA	≥3	≤3	0	3 or more clusters of desaturation events
3	Moderate OSA	≥3	>3	≤3	3 or more clusters of desaturation events
4	Severe OSA	≥3	>3	>3	3 or more clusters of desaturation events

Table 5: Three different intranasal corticosteroids studies in the treatment of obstructive sleep apnea syndrome

Drug	Sample size	Age (year)	Regimen
Mometasone furoate[69]	62	6-18	100 µg/nostril daily for 4 months
Budesonide[70]	62	2-12	32 µg/nostril daily for 6 weeks
Fluticasone propionate[71]	25	1-10	50 µg/nostril twice per day for 1 week, followed by 50 µg/nostril daily for 5 week

Figure 3: Forest plot for the effects of montelukast on apnea–hypopnea index.

Figure 4: Forest plot for the effects of montelukast combined with intranasal steroids on apnea–hypopnea index.

service. Furthermore, a delay in performing TandA should be considered for patients with recent respiratory infections.

Reevaluation with PSG several months after TandA is recommended to evaluate for residual OSAS. There were no studies evaluating the timing of postoperative PSG evaluation. The recommendation of a few months is to allow healing and resolution of inflammation and swelling of the operative site before reassessment.[80,82-84] If PSG is not available, other options outlined in the "management algorithm of OSAS" may be considered.

The prevalence of residual OSAS after TandA ranged from 34% to 87% in the literature, depending on the characteristics of the study population and AHI definition used for residual OSAS.[85] A meta-analysis of the effect of TandA on AHI was undertaken by the authors (DKN, JPN, and SYL). Databases

including PubMed, MEDLINE, EMBASE, and Cochrane Review from 1998 to 2015 were searched. The keywords used included tonsillectomy, adenoidectomy, OSA, sleep apnea, sleep apnea syndrome, and children. Success as defined by postoperative AHI <5 for all children and obese children was 80% and 55%, respectively [Figures 5 and 6], and it decreased to 55% and 30%, respectively, if success was defined as AHI <1–2 [Figures 7 and 8].[79,80,82-84,86-117]

The risk factors for residual OSAS after TandA are severe OSA at baseline, asthma, obesity, or weight gain after TandA, trisomy 21, cerebral palsy, craniofacial abnormalities, upper/lower airway abnormalities, for example, laryngomalacia.[86,93-96,100,105,107,110,114,118-120]

Growth data from the CHAT showed that TandA for OSAS in children resulted in significantly greater than expected weight

Figure 5: Forest plot for success in achieving an apnea–hypopnea index <5 postoperatively in children (not classified by body mass index). There was significant heterogeneity among these studies (I² = 82.53). Data were analyzed with random-effects model estimate.

Figure 6: Forest plot for success in achieving an apnea–hypopnea index <5 postoperatively in obese children. There was significant heterogeneity among these studies (I² = 36.62). Data were analyzed with random-effects model estimate. Obese was defined as Z-score from >1.2, ≥2 to ≥2.33 or body mass index ≥95th percentile.

gain from baseline, even in initially overweight children.[121] This puts overweight children at greater risk of residual or recurrent OSAS after TandA.[120]

The management of residual OSAS after TandA is dependent on the severity of the residual OSAS. Further diagnostic tests (e.g., drug-induced sleep endoscopy [DISE], cine magnetic resonance imaging) to evaluate the level of obstruction may be useful.[63,117,119,121]

Huang *et al.* demonstrated that 53% of children had an AHI >1 at 6-month follow-up after TandA, it increased to 68% at the end of the 36-month follow-up. Risk factors for recurrence of OSAS such as severe OSAS, obesity, and a large increase in body mass index after TandA, allergic rhinitis, enuresis, and older age were identified.[115] Biggs *et al.* performed a 4-year follow-up study for school-aged children (12–16 years old). Improvement in SDB was associated with improvements in

some aspects of neurocognition but not behavior among the children. Therefore, it was suggested that a longer period of follow-up was required to observe the neurocognitive changes.[122] The treatment options for persistent or recurrent OSAS after TandA are listed in Table 6.

ORTHODONTIC TREATMENT

Orthodontic treatment (e.g., rapid maxillary expansion [RME], mandibular advancement devices [MAD]) may be an effective treatment option for childhood OSAS in a selected group of patients. There are, however, limited studies on orthodontic treatment for pediatric OSA, with the majority of studies being nonrandomized clinical trials.

RME is an orthodontic treatment which increases the transverse diameter of the hard palate by reopening the mid-palatal suture with an expandable dental appliance inserted into the

Figure 7: Forest plot for success in achieving an apnea–hypopnea index <1–2 postoperatively in normal children (those have not been classified by body mass index). There was significant heterogeneity among these studies ($I^2 = 85.77$). Data were analyzed with random-effects model estimate.

Figure 8: Forest plot for success in achieving an apnea–hypopnea index <1–2 postoperatively in obese children. There was significant heterogeneity among these studies ($I^2 = 8.11$). Data were analyzed with random-effects model estimate. Obese was defined as Z-score from 1.2 to ≥2.33 or body mass index ≥95th percentile.

mouth close to the hard palate. It also has a secondary impact on placement of the mandible. It may be an option in the management of OSA in children with maxillary contraction, with long-term treatment effect shown in follow-up studies.[113,124-128] A meta-analysis of RME was undertaken by Huynh *et al*. who reported that the AHI decreased by 6.2 after using RME from four studies.[129]

MADs increase the upper airway size by positioning the mandible and tongue forward.[130] In the same review by Huynh *et al*., a meta-analysis of MADs on two studies was undertaken.[129,131,132] With MAD, the AHI decreased by 5.1.

The authors (DKN, JPN, and SYL) updated the meta-analysis by searching databases including PubMed, MEDLINE, EMBASE, and Cochrane Review from 2001 to 2015. The keywords used included sleep apnea, OSA, sleep apnea syndrome, MAD, and children. RevMan (version 5.2, The Cochrane Collaborations, London, UK) was used for the meta-analysis. AHI was found to be decreased by 6.5 with MAD treatment [Figure 9] from three studies.[131-133]

NASAL EXPIRATORY POSITIVE AIRWAY PRESSURE VALVE

This device comprises two small adhesive disposable valves applied to both nares. The valves have negligible resistance during inspiration, but generate resistance during expiration, creating a positive end-expiratory pressure from 4 to 17 cmH$_2$O.[134] Initial studies showed reduction in AHI and symptoms in adults with OSA, but subsequent studies did

Table 6: Treatment options for persistent obstructive sleep apnea syndrome after tonsillectomy and adenoidectomy

Treatments	Comments
Watchful waiting	Generally for mild OSAS, AHI <5, with few or no symptoms and no complications of OSAS
Medical treatment	Nasal corticosteroids and/or leukotriene receptor antagonist[76]
Weight loss	Weight loss is a treatment option for OSAS in overweight/obese children[123]
Positive airway pressure	For moderate/severe OSAS, AHI ≥5
Orthodontic treatment	For mild-to-moderate OSAS
Orofacial myofunctional therapy	For mild-to-moderate OSAS
Other surgical options	Other surgical procedures are considered in a small subset of children with OSAS, after careful evaluation of the upper airway in children with moderate/severe OSAS. Options include tongue surgery, for example, midline glossectomy, genioglossus advancement, maxillo and/or mandibular distraction osteogenesis or tracheostomy[98,113]

OSAS: Obstructive sleep apnea syndrome, AHI: Apnea-hypopnea index

Figure 9: Forest plot for the effects of mandibular advancement device on apnea–hypopnea index.

not show benefit in adults with moderate-to-severe OSA.[135,136] A recent randomized, double-blind, placebo-controlled, crossover pilot study of nasal expiratory positive airway pressure (NEPAP) device on 14 CPAP candidates aged 8–16 years showed significant improvement in OAI with NEPAP in some patients but deterioration in a few patients, suggesting that it must only be prescribed under PSG monitoring.[137]

POSITIVE AIRWAY PRESSURE

The basic mechanism of positive airway pressure (PAP) is to overcome dynamic upper airway obstruction by stenting the airway open by pneumatric pressure. PAP therapy has been found to be effective in improving polysomnographic parameters in pediatric patients with OSAS.[138-143] In addition, there were also improvements in subjective parental assessment of sleepiness, snoring, and difficulty in breathing during sleep.[138] Significant improvement in neurobehavioral function in children after 3 months of PAP therapy was demonstrated, even in developmentally delayed children.[142]

PAP therapy should be considered in children who are not surgical candidates or have contraindications for TandA and those who continue to have moderate/severe OSAS after TandA.[143-145] PAP may also be considered for children with severe preoperative OSAS, co-existing morbidities such as cor pulmonale, morbid obesity, neuromuscular disorders, and craniofacial abnormalities.[87,96]

There are two modes of PAP – continuous positive airway pressure (CPAP) and bi-level positive airway pressure (BPAP).

There is no difference in adherence between CPAP and BPAP.[146] The optimal setting should ideally be adjusted under PSG.[147] The maximum CPAP is 15 cmH$_2$O for <12-year-old children and 20 cmH$_2$O for ≥12-year-old children. CPAP should be switched to BPAP if the patient demonstrates persistence of OSA despite maximum CPAP. For BPAP, the inspiratory positive airway pressure should be started at 4 cm above the expiratory positive airway pressure (EPAP), and the EPAP pressure set at the level eliminates OSA. Long-term follow-up is needed since the required PAP setting may change over time for growing children with change in airway size and structure, as well as body weight.

If PSG titration is not available, the use of auto-titrating PAP devices for titrating pressures can be considered in patients down to 8 months of age without significant comorbidities although the body weight for auto-titrating PAP is usually above 30 kg.[148] PAP also can be titrated under DISE in selected centers with expertise.

In areas where none of the above are available, one may offer CPAP with pressure around 6–8 cmH2O for nonobese nonsyndromic OSAS and 8–10 cm for obese nonsyndromic children and to monitor for clinical response.[139] Data downloaded from PAP machines are useful in monitoring treatment adherence as parental reports are often not reliable.[146]

Adherence is the major barrier to PAP as an effective therapy for childhood OSAS.[146,149,150] Behavioral intervention, education, training, and close follow-up were shown to improve PAP adherence.[151]

Study or Subgroup	Before Mean	SD	Total	After Mean	SD	Total	Weight	Mean Difference IV, Random, 95% CI	Year
Guilleminault C 2013	0.4	0.3	11	0.5	0.4	11	45.3%	-0.10 [-0.40, 0.20]	2013
Villa MP 2014	4.87	2.96	14	1.84	3.22	14	18.6%	3.03 [0.74, 5.32]	2014
Lee SY 2015	1.91	1.36	18	1.1	1.19	9	36.1%	0.81 [-0.19, 1.81]	2015
Total (95% CI)			43			34	100.0%	0.81 [-0.46, 2.09]	

Heterogeneity: Tau² = 0.91; Chi² = 9.66, df = 2 (P = 0.008); I² = 79%
Test for overall effect: Z = 1.25 (P = 0.21)

Figure 10: Forest plot for the effects of myofunctional therapy on apnea–hypopnea index.

A proper interface is crucial for the successful administration of PAP. The ideal interface should ensure comfort and fit, while minimizing leak.[152] Excessive leak can impact on sleep quality, patient–ventilator synchrony, and the amount of effective ventilation delivered to the patient.[153] If a child mouth breathes significantly, a chin strap should be used.

PAP should be provided with a heated humidifier because of the high flow of dry room air that would overwhelm the capacity of the nose to humidify and warm the incoming air. Notwithstanding the above measure, some patients would still have prominent nasal symptoms that would benefit from intranasal steroids. Skin irritation and ulceration can occur from a tight-fitting mask or from accumulation of skin oils and debris from poor mask maintenance.[154-157] Mid-facial hypoplasia was reported with long-term use of nasal CPAP.[158] A study showed that nasal PAP compliant individuals experienced a retrusion of the mid-face after a few years.[159] Use of nasal mask and nasal pillow on alternate nights might be tried to avoid the pressure effect on mid-face. Facial profile should be assessed every year for adverse impact on growth. For children requiring chin strap, the effect on the mandibular condyle should also be assessed yearly.

OROFACIAL MYOFUNCTIONAL THERAPY

Orofacial myofunctional therapy (OMT) is potentially an option for the treatment of OSAS. It is defined as the treatment for the muscles of the face and mouth, which is crucial for the maintenance of the craniofacial integrity to achieve normal nasal breathing.[160] OMT reeducation trains a normal and strong sucking, a good mastication employing both sides of jaw, normal swallowing, normal tongue position, and nasal breathing with lips in good contact at rest.[13] Nasal breathing during wake and sleep is the demonstration of normal respiratory functioning, and persistence of mouth breathing is an indicator of an abnormal respiratory function.[161]

Guilleminault *et al*. reported a retrospective study of 11 children who received OMT.[162] The exercise group was followed up for the first 6 months. Exercise was repeated several times daily in the first 6 months. At 4-year follow-up, the exercise group remained cured of OSA (AHI 0.5 ± 0.4/h) compared to the control group which had a recurrence of OSA (AHI 5.3 ± 1.5/h).

In a prospective, randomized controlled study done by Villa *et al*., 27 post-TandA children were randomized to either OMT or control group.[163] Children were required to

perform exercises every day at home, at least three times a day, 10–20 repetitions each time. Both groups performed nasal washing twice a day. The treatment group consisted of 14 patients and their pre- and post-exercise AHI was evaluated after 2 months of OMT. The AHI decreased from 4.9 to 1.8 (P = 0.004) while the control group had minimal change in AHI (4.6–4.1).

In a retrospective case series study done by Lee *et al*., 26 children out of 64 children had persistent SDB after TandA and 35 of the 64 children showed a pattern of mouth breathing.[161] Eighteen children of the mouth breathing group were followed up for a year with OMT offered. However, only nine of them underwent 6 months of OMT three times a week. The non-OMT group showed a significant worse AHI, 2.9, when compared to the exercise group, 1.1.

A forest plot was constructed with RevMan (version 5.2, The Cochrane Collaborations, London, UK) for the studies of Villa *et al*., Guilleminault *et al*., and Lee *et al*. by the authors (DKN, JPN, and SYL, respectively). The overall AHI was reduced by 0.81 with 95% confidence interval crossing zero [Figure 10]. Hence, further studies are warranted for OMT in childhood OSAS.

CONCLUSION

This is the first position statement on the management of childhood OSA in Asia, which would serve as a guideline for doctors in this area so that a more uniform approach can be adopted for this disease. While there are still considerable knowledge gap in this area, this statement provides the foundation for future studies.

REFERENCES

1. Marcus CL, Brooks LJ, Draper KA, Gozal D, Halbower AC, Jones J, *et al*. Diagnosis and management of childhood obstructive sleep apnea syndrome. Pediatrics 2012;130:576-84.

2. Li AM, So HK, Au CT, Ho C, Lau J, Ng SK, *et al.* Epidemiology of obstructive sleep apnoea syndrome in Chinese children: A two-phase community study. Thorax 2010;65:991-7.

3. Marcus CL, Brooks LJ, Draper KA, Gozal D, Halbower AC, Jones J, *et al.* Diagnosis and management of childhood obstructive sleep apnea syndrome. Pediatrics 2012;130:576-84.

4. Kaditis AG, Alonso Alvarez ML, Boudewyns A, Alexopoulos EI, Ersu R, Joosten K, *et al.* Obstructive sleep disordered breathing in 2- to 18-year-old children: Diagnosis and management. Eur Respir J 2016;47:69-94.

5. Ng DK, Chan CH. A review of normal values of infant sleep polysomnography. Pediatr Neonatol 2013;54:82-7.

6. Wise MS, Nichols CD, Grigg-Damberger MM, Marcus CL, Witmans MB, Kirk VG, *et al.* Executive summary of respiratory indications for polysomnography in children: An evidence-based review. Sleep 2011;34:389-98AW.

7. Schwab RJ, Kim C, Bagchi S, Keenan BT, Comyn FL, Wang S, *et al.* Understanding the anatomic basis for obstructive sleep apnea syndrome in adolescents. Am J Respir Crit Care Med 2015;191:1295-309.

8. Wilhelm CP, deShazo RD, Tamanna S, Ullah MI, Skipworth LB. The nose, upper airway, and obstructive sleep apnea. Ann Allergy Asthma Immunol 2015;115:96-102.

9. Ng DK, Chan CH, Hwang GY, Chow PY, Kwok KL. A review of the roles of allergic rhinitis in childhood obstructive sleep apnea syndrome. Allergy Asthma Proc 2006;27:240-2.

10. Wing YK, Hui SH, Pak WM, Ho CK, Cheung A, Li AM, *et al.* A controlled study of sleep related disordered breathing in obese children. Arch Dis Child 2003;88:1043-7.

11. Lam YY, Chan EY, Ng DK, Chan CH, Cheung JM, Leung SY, *et al.* The correlation among obesity, apnea-hypopnea index, and tonsil size in children. Chest 2006;130:1751-6.

12. Xu Z, Jiaqing A, Yuchuan L, Shen K. A case-control study of obstructive sleep apnea-hypopnea syndrome in obese and nonobese Chinese children. Chest 2008;133:684-9.

13. Guilleminault C, Akhtar F. Pediatric sleep-disordered breathing: New evidence on its development. Sleep Med Rev 2015;24:46-56.

14. Dyken ME, Lin-Dyken DC, Poulton S, Zimmerman MB, Sedars E. Prospective polysomnographic analysis of obstructive sleep apnea in Down syndrome. Arch Pediatr Adolesc Med 2003;157:655-60.

15. Williams K, Scheimann A, Sutton V, Hayslett E, Glaze DG. Sleepiness and sleep disordered breathing in Prader-Willi syndrome: Relationship to genotype, growth hormone therapy, and body composition. J Clin Sleep Med 2008;4:111-8.

16. Huang YS, Guilleminault C. Pediatric obstructive sleep apnea and the critical role of oral-facial growth: Evidences. Front Neurol 2013;3:184.

17. Huang YS, Quo S, Berkowski JA, Guilleminault C. Short lingual frenulum and obstructive sleep apnea in children. Int J Pediatr Res 2015;1:1-4.

18. Huang YS, Hwang FM, Lin CH, Lee LA, Huang PY, Chiu ST. Clinical manifestations of pediatric obstructive sleep apnea syndrome: Clinical utility of the Chinese-version Obstructive Sleep Apnea Questionaire-18. Psychiatry Clin Neurosci 2015;69:752-62.

19. Suresh S, Wales P, Dakin C, Harris MA, Cooper DG. Sleep-related breathing disorder in Duchenne muscular dystrophy: Disease spectrum in the paediatric population. J Paediatr Child Health 2005;41:500-3.

20. Dauvilliers Y, Stal V, Abril B, Coubes P, Bobin S, Touchon J, *et al.* Chiari malformation and sleep related breathing disorders. J Neurol Neurosurg Psychiatry 2007;78:1344-8.

21. Hibbs AM, Johnson NL, Rosen CL, Kirchner HL, Martin R, Storfer-Isser A, *et al.* Prenatal and neonatal risk factors for sleep disordered breathing in school-aged children born preterm. J Pediatr 2008;153:176-82.

22. Weinstock TG, Rosen CL, Marcus CL, Garetz S, Mitchell RB, Amin R, *et al.* Predictors of obstructive sleep apnea severity in adenotonsillectomy candidates. Sleep 2014;37:261-9.

23. Zhu Y, Au CT, Leung TF, Wing YK, Lam CW, Li AM. Effects of passive smoking on snoring in preschool children. J Pediatr 2013;163:1158-62. e4.

24. Spruyt K, Gozal D. A mediation model linking body weight, cognition, and sleep-disordered breathing. Am J Respir Crit Care Med 2012;185:199-205.

25. Hogan AM, Hill CM, Harrison D, Kirkham FJ. Cerebral blood flow velocity and cognition in children before and after adenotonsillectomy. Pediatrics 2008;122:75-82.

26. Biggs SN, Walter LM, Jackman AR, Nisbet LC, Weichard AJ, Hollis SL, *et al.* Long-term cognitive and behavioral outcomes following resolution of sleep disordered breathing in preschool children. PLoS One 2015;10:e0139142.

27. Quan SF, Archbold K, Gevins AS, Goodwin JL. Long-term neurophysiologic impact of childhood sleep disordered breathing on neurocognitive performance. Southwest J Pulm Crit Care 2013;7:165-75.

28. Chan JY, Li AM, Au CT, Lo AF, Ng SK, Abdullah VJ, *et al.* Cardiac remodelling and dysfunction in children with obstructive sleep apnoea: A community based study. Thorax 2009;64:233-9.

29. Li AM, Au CT, Sung RY, Ho C, Ng PC, Fok TF, *et al.* Ambulatory blood pressure in children with obstructive sleep apnoea: A community based study. Thorax 2008;63:803-9.

30. Mulvaney SA, Goodwin JL, Morgan WJ, Rosen GR, Quan SF, Kaemingk KL. Behavior problems associated with sleep disordered breathing in school-aged children – The Tucson children's assessment of sleep apnea study. J Pediatr Psychol 2006;31:322-30.

31. Chervin RD, Archbold KH. Hyperactivity and polysomnographic findings in children evaluated for sleep-disordered breathing. Sleep 2001;24:313-20.

32. Song SA, Tolisano AM, Cable BB, Camacho M. Neurocognitive outcomes after pediatric adenotonsillectomy for obstructive sleep apnea: A systematic review and meta-analysis. Int J Pediatr Otorhinolaryngol 2016;83:205-10.

33. Chan KC, Shi L, So HK, Wang D, Liew AW, Rasalkar DD, *et al.* Neurocognitive dysfunction and grey matter density deficit in children with obstructive sleep apnoea. Sleep Med 2014;15:1055-61.

34. Cortese S, Faraone SV, Konofal E, Lecendreux M. Sleep in children with attention-deficit/hyperactivity disorder: Meta-analysis of subjective and objective studies. J Am Acad Child Adolesc Psychiatry 2009;48:894-908.

35. Guilleminault C, Lee JH, Chan A, Lopes MC, Huang YS, da Rosa A. Non-REM-sleep instability in recurrent sleepwalking in pre-pubertal children. Sleep Med 2005;6:515-21.

36. Carotenuto M, Esposito M, Parisi L, Gallai B, Marotta R, Pascotto A, *et al.* Depressive symptoms and childhood sleep apnea syndrome. Neuropsychiatr Dis Treat 2012;8:369-73.

37. Kukwa W, Kukwa A, Galazka A, Grochowski T, Krzeski A, Gronkiewicz Z, *et al.* Snoring but not BMI influences aggressive behavior and concentration problems in children. Otolaryngol Pol 2015;69:22-9.

38. Yue W, Hao W, Liu P, Liu T, Ni M, Guo Q. A case-control study on psychological symptoms in sleep apnea-hypopnea syndrome. Can J Psychiatry 2003;48:318-23.

39. Brooks LJ, Topol HI. Enuresis in children with sleep apnea. J Pediatr 2003;142:515-8.

40. Khositseth A, Chokechuleekorn J, Kuptanon T, Leejakpai A. Rhythm disturbances in childhood obstructive sleep apnea during apnea-hypopnea episodes. Ann Pediatr Cardiol 2013;6:39-42.

41. Constantin E, McGregor CD, Cote V, Brouillette RT. Pulse rate and pulse rate variability decrease after adenotonsillectomy for obstructive sleep apnea. Pediatr Pulmonol 2008;43:498-504.

42. O'Brien LM, Gozal D. Autonomic dysfunction in children with sleep-disordered breathing. Sleep 2005;28:747-52.

43. Kwok KL, Ng DK, Cheung YF. BP and arterial distensibility in children with primary snoring. Chest 2003;123:1561-6.

44. Hakim F, Gozal D, Kheirandish-Gozal L. Sympathetic and catecholaminergic alterations in sleep apnea with particular emphasis on children. Front Neurol 2012;3:7.

45. Chaicharn J, Lin Z, Chen ML, Ward SL, Keens T, Khoo MC. Model-based assessment of cardiovascular autonomic control in children with obstructive sleep apnea. Sleep 2009;32:927-38.

46. Chan KC, Au CT, Chook P, Lee DL, Lam HS, Wing YK, *et al.* Endothelial function in children with OSA and the effects of adenotonsillectomy. Chest 2015;147:132-9.

47. Nieminen P, Löppönen T, Tolonen U, Lanning P, Knip M, Löppönen H. Growth and biochemical markers of growth in children with snoring and obstructive sleep apnea. Pediatrics 2002;109:e55.
48. Marcus CL, Carroll JL, Koerner CB, Hamer A, Lutz J, Loughlin GM. Determinants of growth in children with the obstructive sleep apnea syndrome. J Pediatr 1994;125:556-62.
49. Schnall RP, Shlitner A, Sheffy J, Kedar R, Lavie P. Periodic, profound peripheral vasoconstriction – A new marker of obstructive sleep apnea. Sleep 1999;22:939-46.
50. O'Brien LM, Gozal D. Potential usefulness of noninvasive autonomic monitoring in recognition of arousals in normal healthy children. J Clin Sleep Med 2007;3:41-7.
51. Brouillette RT, Morielli A, Leimanis A, Waters KA, Luciano R, Ducharme FM. Nocturnal pulse oximetry as an abbreviated testing modality for pediatric obstructive sleep apnea. Pediatrics 2000;105:405-12.
52. Nixon GM, Kermack AS, Davis GM, Manoukian JJ, Brown KA, Brouillette RT. Planning adenotonsillectomy in children with obstructive sleep apnea: The role of overnight oximetry. Pediatrics 2004;113(1 Pt 1):e19-25.
53. Pavone M, Cutrera R, Verrillo E, Salerno T, Soldini S, Brouillette RT. Night-to-night consistency of at-home nocturnal pulse oximetry testing for obstructive sleep apnea in children. Pediatr Pulmonol 2013;48:754-60.
54. Sher AE, Shprintzen RJ, Thorpy MJ. Endoscopic observations of obstructive sleep apnea in children with anomalous upper airways: Predictive and therapeutic value. Int J Pediatr Otorhinolaryngol 1986;11:135-46.
55. Croft CB, Thomson HG, Samuels MP, Southall DP. Endoscopic evaluation and treatment of sleep-associated upper airway obstruction in infants and young children. Clin Otolaryngol Allied Sci 1990;15:209-16.
56. Contencin P, Nottet JB, Yacoubian K, Soussi T, Nivoche Y, Narcy P. Pharyngolaryngeal fibroscopy under general anesthesia in children. Technique and indications in sleep apnea and hypopnea. Ann Otolaryngol Chir Cervicofac 1991;108:373-7.
57. Myatt HM, Beckenham EJ. The use of diagnostic sleep nasendoscopy in the management of children with complex upper airway obstruction. Clin Otolaryngol Allied Sci 2000;25:200-8.
58. Goldberg S, Shatz A, Picard E, Wexler I, Schwartz S, Swed E, et al. Endoscopic findings in children with obstructive sleep apnea: Effects of age and hypotonia. Pediatr Pulmonol 2005;40:205-10.
59. Thevasagayam M, Rodger K, Cave D, Witmans M, El-Hakim H. Prevalence of laryngomalacia in children presenting with sleep-disordered breathing. Laryngoscope 2010;120:1662-6.
60. Fung E, Witmans M, Ghosh M, Cave D, El-Hakim H. Upper airway findings in children with Down syndrome on sleep nasopharyngoscopy: Case-control study. J Otolaryngol Head Neck Surg 2012;41:138-44.
61. Koo SK, Choi JW, Myung NS, Lee HJ, Kim YJ, Kim YJ. Analysis of obstruction site in obstructive sleep apnea syndrome patients by drug induced sleep endoscopy. Am J Otolaryngol 2013;34:626-30.
62. Truong MT, Woo VG, Koltai PJ. Sleep endoscopy as a diagnostic tool in pediatric obstructive sleep apnea. Int J Pediatr Otorhinolaryngol 2012;76:722-7.
63. Durr ML, Meyer AK, Kezirian EJ, Rosbe KW. Drug-induced sleep endoscopy in persistent pediatric sleep-disordered breathing after adenotonsillectomy. Arch Otolaryngol Head Neck Surg 2012;138:638-43.
64. Ulualp SO, Szmuk P. Drug-induced sleep endoscopy for upper airway evaluation in children with obstructive sleep apnea. Laryngoscope 2013;123:292-7.
65. Psaltis AJ, Li G, Vaezeafshar R, Cho KS, Hwang PH. Modification of the Lund-Kennedy endoscopic scoring system improves its reliability and correlation with patient-reported outcome measures. Laryngoscope 2014;124:2216-23.
66. Chan DK, Liming BJ, Horn DL, Parikh SR. A new scoring system for upper airway pediatric sleep endoscopy. JAMA Otolaryngol Head Neck Surg 2014;140:595-602.
67. Konermann M, Radü HJ, Teschler H, Rawert B, Heimbucher J, Sanner BM. Interaction of sleep disturbances and gastroesophageal reflux in chronic laryngitis. Am J Otolaryngol 2002;23:20-6.
68. Alexopoulos EI, Kaditis AG, Kalampouka E, Kostadima E, Angelopoulos NV, Mikraki V, et al. Nasal corticosteroids for children with snoring. Pediatr Pulmonol 2004;38:161-7.
69. Chan CC, Au CT, Lam HS, Lee DL, Wing YK, Li AM. Intranasal corticosteroids for mild childhood obstructive sleep apnea – A randomized, placebo-controlled study. Sleep Med 2015;16:358-63.
70. Kheirandish-Gozal L, Gozal D. Intranasal budesonide treatment for children with mild obstructive sleep apnea syndrome. Pediatrics 2008;122:e149-55.
71. Brouillette RT, Manoukian JJ, Ducharme FM, Oudjhane K, Earle LG, Ladan S, et al. Efficacy of fluticasone nasal spray for pediatric obstructive sleep apnea. J Pediatr 2001;138:838-44.
72. Liu HT, Lin YC, Kuan YC, Huang YH, Hou WH, Liou TH, et al. Intranasal corticosteroid therapy in the treatment of obstructive sleep apnea: A meta-analysis of randomized controlled trials. Am J Rhinol Allergy 2016;30:215-21.
73. Goldbart AD, Goldman JL, Veling MC, Gozal D. Leukotriene modifier therapy for mild sleep-disordered breathing in children. Am J Respir Crit Care Med 2005;172:364-70.
74. Goldbart AD, Greenberg-Dotan S, Tal A. Montelukast for children with obstructive sleep apnea: A double-blind, placebo-controlled study. Pediatrics 2012;130:e575-80.
75. Kheirandish-Gozal L, Bandla HP, Gozal D. Montelukast for children with obstructive sleep apnea: Results of a double-blind, randomized, placebo-controlled trial. Ann Am Thorac Soc 2016;13:1736-41.
76. Kheirandish L, Goldbart AD, Gozal D. Intranasal steroids and oral leukotriene modifier therapy in residual sleep-disordered breathing after tonsillectomy and adenoidectomy in children. Pediatrics 2006;117:e61-6.
77. Kheirandish-Gozal L, Bhattacharjee R, Bandla HP, Gozal D. Antiinflammatory therapy outcomes for mild OSA in children. Chest 2014;146:88-95.
78. Redline S, Amin R, Beebe D, Chervin RD, Garetz SL, Giordani B, et al. The Childhood Adenotonsillectomy Trial (CHAT): Rationale, design, and challenges of a randomized controlled trial evaluating a standard surgical procedure in a pediatric population. Sleep 2011;34:1509-17.
79. Marcus CL, Moore RH, Rosen CL, Giordani B, Garetz SL, Taylor HG, et al. A randomized trial of adenotonsillectomy for childhood sleep apnea. N Engl J Med 2013;368:2366-76.
80. Mitchell RB, Kelly J. Outcome of adenotonsillectomy for obstructive sleep apnea in children under 3 years. Otolaryngol Head Neck Surg 2005;132:681-4.
81. Ma AL, Lam YY, Wong SF, Ng DK, Chan CH. Risk factors for post-operative complications in Chinese children with tonsillectomy and adenoidectomy for obstructive sleep apnea syndrome. Sleep Breath 2012;16:909-11.
82. Mitchell RB, Kelly J. Outcome of adenotonsillectomy for severe obstructive sleep apnea in children. Int J Pediatr Otorhinolaryngol 2004;68:1375-9.
83. Walker P, Whitehead B, Gulliver T. Polysomnographic outcome of adenotonsillectomy for obstructive sleep apnea in children under 5 years old. Otolaryngol Head Neck Surg 2008;139:83-6.
84. Ng DK, Wong JC, Chan CH, Leung LC, Leung SY. Ambulatory blood pressure before and after adenotonsillectomy in children with obstructive sleep apnea. Sleep Med 2010;11:721-5.
85. Lee CH, Hsu WC, Chang WH, Lin MT, Kang KT. Polysomnographic findings after adenotonsillectomy for obstructive sleep apnoea in obese and non-obese children: A systematic review and meta-analysis. Clin Otolaryngol 2016;41:498-510.
86. Nath A, Emani J, Suskind DL, Baroody FM. Predictors of persistent sleep apnea after surgery in children younger than 3 years. JAMA Otolaryngol Head Neck Surg 2013;139:1002-8.
87. Suen JS, Arnold JE, Brooks LJ. Adenotonsillectomy for treatment of obstructive sleep apnea in children. Arch Otolaryngol Head Neck Surg 1995;121:525-30.
88. Nishimura T, Morishima N, Hasegawa S, Shibata N, Iwanaga K, Yagisawa M. Effect of surgery on obstructive sleep apnea. Acta Otolaryngol Suppl 1996;523:231-3.
89. Wang RC, Elkins TP, Keech D, Wauquier A, Hubbard D. Accuracy of

90. Tal A, Bar A, Leiberman A, Tarasiuk A. Sleep characteristics following adenotonsillectomy in children with obstructive sleep apnea syndrome. Chest 2003;124:948-53.

91. Goldstein NA, Pugazhendhi V, Rao SM, Weedon J, Campbell TF, Goldman AC, *et al.* Clinical assessment of pediatric obstructive sleep apnea. Pediatrics 2004;114:33-43.

92. Mitchell RB, Kelly J. Adenotonsillectomy for obstructive sleep apnea in obese children. Otolaryngol Head Neck Surg 2004;131:104-8.

93. Tauman R, Gulliver TE, Krishna J, Montgomery-Downs HE, O'Brien LM, Ivanenko A, *et al.* Persistence of obstructive sleep apnea syndrome in children after adenotonsillectomy. J Pediatr 2006;149:803-8.

94. O'Brien LM, Sitha S, Baur LA, Waters KA. Obesity increases the risk for persisting obstructive sleep apnea after treatment in children. Int J Pediatr Otorhinolaryngol 2006;70:1555-60.

95. Mitchell RB. Adenotonsillectomy for obstructive sleep apnea in children: Outcome evaluated by pre- and postoperative polysomnography. Laryngoscope 2007;117:1844-54.

96. Mitchell RB, Kelly J. Outcome of adenotonsillectomy for obstructive sleep apnea in obese and normal-weight children. Otolaryngol Head Neck Surg 2007;137:43-8.

97. Gozal D, Capdevila OS, Kheirandish-Gozal L. Metabolic alterations and systemic inflammation in obstructive sleep apnea among nonobese and obese prepubertal children. Am J Respir Crit Care Med 2008;177:1142-9.

98. Friedman M, Samuelson CG, Hamilton C, Maley A, Taylor D, Kelley K, *et al.* Modified adenotonsillectomy to improve cure rates for pediatric obstructive sleep apnea: A randomized controlled trial. Otolaryngol Head Neck Surg 2012;147:132-8.

99. Baldassari CM, Kepchar J, Bryant L, Beydoun H, Choi S. Changes in central apnea index following pediatric adenotonsillectomy. Otolaryngol Head Neck Surg 2012;146:487-90.

100. Hsu WC, Kang KT, Weng WC, Lee PL. Impacts of body weight after surgery for obstructive sleep apnea in children. Int J Obes (Lond) 2013;37:527-31.

101. Kang KT, Weng WC, Lee CH, Lee PL, Hsu WC. Discrepancy between objective and subjective outcomes after adenotonsillectomy in children with obstructive sleep apnea syndrome. Otolaryngol Head Neck Surg 2014;151:150-8.

102. Jeong JH, Guilleminault C, Park CS, Son HL, Lee HK, Hwang SH, *et al.* Changes in salivary cortisol levels in pediatric patients with obstructive sleep apnea syndrome after adenotonsillectomy. Sleep Med 2014;15:672-6.

103. Lee LA, Li HY, Lin YS, Fang TJ, Huang YS, Hsu JF, *et al.* Severity of childhood obstructive sleep apnea and hypertension improved after adenotonsillectomy. Otolaryngol Head Neck Surg 2015;152:553-60.

104. Suri JC, Sen MK, Venkatachalam VP, Bhool S, Sharma R, Elias M, *et al.* Outcome of adenotonsillectomy for children with sleep apnea. Sleep Med 2015;16:1181-6.

105. Shine NP, Lannigan FJ, Coates HL, Wilson A. Adenotonsillectomy for obstructive sleep apnea in obese children: Effects on respiratory parameters and clinical outcome. Arch Otolaryngol Head Neck Surg 2006;132:1123-7.

106. Com G, Carroll JL, Tang X, Melguizo MS, Bower C, Jambhekar S. Characteristics and surgical and clinical outcomes of severely obese children with obstructive sleep apnea. J Clin Sleep Med 2015;11:467-74.

107. Shintani T, Asakura K, Kataura A. The effect of adenotonsillectomy in children with OSA. Int J Pediatr Otorhinolaryngol 1998;44:51-8.

108. Nieminen P, Tolonen U, Löppönen H. Snoring and obstructive sleep apnea in children: A 6-month follow-up study. Arch Otolaryngol Head Neck Surg 2000;126:481-6.

109. Stewart MG, Glaze DG, Friedman EM, Smith EO, Bautista M. Quality of life and sleep study findings after adenotonsillectomy in children with obstructive sleep apnea. Arch Otolaryngol Head Neck Surg 2005;131:308-14.

110. Guilleminault C, Huang YS, Glamann C, Li K, Chan A. Adenotonsillectomy and obstructive sleep apnea in children: A prospective survey. Otolaryngol Head Neck Surg 2007;136:169-75.

111. Tunkel DE, Hotchkiss KS, Carson KA, Sterni LM. Efficacy of powered intracapsular tonsillectomy and adenoidectomy. Laryngoscope 2008;118:1295-302.

112. Reilly BK, Levin J, Sheldon S, Harsanyi K, Gerber ME. Efficacy of microdebrider intracapsular adenotonsillectomy as validated by polysomnography. Laryngoscope 2009;119:1391-3.

113. Villa MP, Castaldo R, Miano S, Paolino MC, Vitelli O, Tabarrini A, *et al.* Adenotonsillectomy and orthodontic therapy in pediatric obstructive sleep apnea. Sleep Breath 2014;18:533-9.

114. Bhushan B, Sheldon S, Wang E, Schroeder JW Jr. Clinical indicators that predict the presence of moderate to severe obstructive sleep apnea after adenotonsillectomy in children. Am J Otolaryngol 2014;35:487-95.

115. Huang YS, Guilleminault C, Lee LA, Lin CH, Hwang FM. Treatment outcomes of adenotonsillectomy for children with obstructive sleep apnea: A prospective longitudinal study. Sleep 2014;37:71-6.

116. Kobayashi R, Miyazaki S, Karaki M, Hoshikawa H, Nakata S, Hara H, *et al.* Evaluation of adenotonsillectomy and tonsillectomy for pediatric obstructive sleep apnea by rhinomanometry and the OSA-18 questionnaire. Acta Otolaryngol 2014;134:818-23.

117. Nandalike K, Shifteh K, Sin S, Strauss T, Stakofsky A, Gonik N, *et al.* Adenotonsillectomy in obese children with obstructive sleep apnea syndrome: Magnetic resonance imaging findings and considerations. Sleep 2013;36:841-7.

118. Ye J, Liu H, Zhang GH, Li P, Yang QT, Liu X, *et al.* Outcome of adenotonsillectomy for obstructive sleep apnea syndrome in children. Ann Otol Rhinol Laryngol 2010;119:506-13.

119. Donnelly LF, Shott SR, LaRose CR, Chini BA, Amin RS. Causes of persistent obstructive sleep apnea despite previous tonsillectomy and adenoidectomy in children with down syndrome as depicted on static and dynamic cine MRI. AJR Am J Roentgenol 2004;183:175-81.

120. Bhattacharjee R, Kheirandish-Gozal L, Spruyt K, Mitchell RB, Promchiarak J, Simakajornboon N, *et al.* Adenotonsillectomy outcomes in treatment of obstructive sleep apnea in children: A multicenter retrospective study. Am J Respir Crit Care Med 2010;182:676-83.

121. Katz ES, Moore RH, Rosen CL, Mitchell RB, Amin R, Arens R, *et al.* Growth after adenotonsillectomy for obstructive sleep apnea: An RCT. Pediatrics 2014;134:282-9.

122. Biggs SN, Vlahandonis A, Anderson V, Bourke R, Nixon GM, Davey MJ, *et al.* Long-term changes in neurocognition and behavior following treatment of sleep disordered breathing in school-aged children. Sleep 2014;37:77-84.

123. Verhulst SL, Franckx H, Van Gaal L, De Backer W, Desager K. The effect of weight loss on sleep-disordered breathing in obese teenagers. Obesity (Silver Spring) 2009;17:1178-83.

124. Pirelli P, Saponara M, Guilleminault C. Rapid maxillary expansion in children with obstructive sleep apnea syndrome. Sleep 2004;27:761-6.

125. Pirelli P, Saponara M, Guilleminault C. Rapid maxillary expansion (RME) for pediatric obstructive sleep apnea: A 12-year follow-up. Sleep Med 2015;16:933-5.

126. Villa MP, Malagola C, Pagani J, Montesano M, Rizzoli A, Guilleminault C, *et al.* Rapid maxillary expansion in children with obstructive sleep apnea syndrome: 12-month follow-up. Sleep Med 2007;8:128-34.

127. Villa MP, Rizzoli A, Miano S, Malagola C. Efficacy of rapid maxillary expansion in children with obstructive sleep apnea syndrome: 36 months of follow-up. Sleep Breath 2011;15:179-84.

128. Guilleminault C, Monteyrol PJ, Huynh NT, Pirelli P, Quo S, Li K. Adeno-tonsillectomy and rapid maxillary distraction in pre-pubertal children, a pilot study. Sleep Breath 2011;15:173-7.

129. Huynh NT, Desplats E, Almeida FR. Orthodontics treatments for managing obstructive sleep apnea syndrome in children: A systematic review and meta-analysis. Sleep Med Rev 2016;25:84-94.

130. Ramar K, Dort LC, Katz SG, Lettieri CJ, Harrod CG, Thomas SM, *et al.* Clinical practice guideline for the treatment of obstructive sleep apnea and snoring with oral appliance therapy: An update for 2015. J Clin Sleep Med 2015;11:773-827.

131. Cozza P, Ballanti F, Prete L. A modified monobloc for treatment of young children with obstructive sleep apnea. J Clin Orthod 2004;38:241-7.

132. Villa MP, Bernkopf E, Pagani J, Broia V, Montesano M, Ronchetti R. Randomized controlled study of an oral jaw-positioning appliance for

the treatment of obstructive sleep apnea in children with malocclusion. Am J Respir Crit Care Med 2002;165:123-7.

133. Zhang C, He H, Ngan P. Effects of twin block appliance on obstructive sleep apnea in children: A preliminary study. Sleep Breath 2013;17:1309-14.

134. Braga CW, Chen Q, Burschtin OE, Rapoport DM, Ayappa I. Changes in lung volume and upper airway using MRI during application of nasal expiratory positive airway pressure in patients with sleep-disordered breathing. J Appl Physiol 2011;111:1400-9.

135. Kryger MH, Berry RB, Massie CA. Long-term use of a nasal expiratory positive airway pressure (EPAP) device as a treatment for obstructive sleep apnea (OSA). J Clin Sleep Med 2011;7:449-53B.

136. Rossi VA, Winter B, Rahman NM, Yu LM, Fallon J, Clarenbach CF, *et al.* The effects of Provent on moderate to severe obstructive sleep apnoea during continuous positive airway pressure therapy withdrawal: A randomised controlled trial. Thorax 2013;68:854-9.

137. Kureshi SA, Gallagher PR, McDonough JM, Cornaglia MA, Maggs J, Samuel J, *et al.* Pilot study of nasal expiratory positive airway pressure devices for the treatment of childhood obstructive sleep apnea syndrome. J Clin Sleep Med 2014;10:663-9.

138. Marcus CL, Beck SE, Traylor J, Cornaglia MA, Meltzer LJ, DiFeo N, *et al.* Randomized, double-blind clinical trial of two different modes of positive airway pressure therapy on adherence and efficacy in children. J Clin Sleep Med 2012;8:37-42.

139. Marcus CL, Ward SL, Mallory GB, Rosen CL, Beckerman RC, Weese-Mayer DE, *et al.* Use of nasal continuous positive airway pressure as treatment of childhood obstructive sleep apnea. J Pediatr 1995;127:88-94.

140. Waters KA, Everett FM, Bruderer JW, Sullivan CE. Obstructive sleep apnea: The use of nasal CPAP in 80 children. Am J Respir Crit Care Med 1995;152:780-5.

141. Guilleminault C, Pelayo R, Clerk A, Leger D, Bocian RC. Home nasal continuous positive airway pressure in infants with sleep-disordered breathing. J Pediatr 1995;127:905-12.

142. Marcus CL, Radcliffe J, Konstantinopoulou S, Beck SE, Cornaglia MA, Traylor J, *et al.* Effects of positive airway pressure therapy on neurobehavioral outcomes in children with obstructive sleep apnea. Am J Respir Crit Care Med 2012;185:998-1003.

143. Smith DF, Benke JR, Yaster S, Boss EF, Ishman SL. A pilot staging system to predict persistent obstructive sleep apnea in children following adenotonsillectomy: Predicting persistent pediatric OSA. Laryngoscope 2013;123:1817-22.

144. Marcus CL, Brooks LJ, Draper KA, Gozal D, Halbower AC, Jones J, *et al*. Diagnosis and management of childhood obstructive sleep apnea syndrome. Pediatrics 2012;130:e714-55.

145. Preutthipan A, Sritippayawan S, Kuptanon T. Thai Guideline for Childhood Obstructive Sleep Apnea; 2013. Available from: http://www.thaipedlung.org. [Last accessed on 2016 Mar 23].

146. Marcus CL, Rosen G, Ward SL, Halbower AC, Sterni L, Lutz J, *et al.* Adherence to and effectiveness of positive airway pressure therapy in children with obstructive sleep apnea. Pediatrics 2006;117:e442-51.

147. Kushida CA, Chediak A, Berry RB, Brown LK, Gozal D, Iber C, *et al.* Clinical guidelines for the manual titration of positive airway pressure in patients with obstructive sleep apnea. J Clin Sleep Med 2008;4:157-71.

148. Palombini L, Pelayo R, Guilleminault C. Efficacy of automated continuous positive airway pressure in children with sleep-related breathing disorders in an attended setting. Pediatrics 2004;113:e412-7.

149. Uong EC, Epperson M, Bathon SA, Jeffe DB. Adherence to nasal positive airway pressure therapy among school-aged children and adolescents with obstructive sleep apnea syndrome. Pediatrics 2007;120:e1203-11.

150. O'Donnell AR, Bjornson CL, Bohn SG, Kirk VG. Compliance rates in children using noninvasive continuous positive airway pressure. Sleep 2006;29:651-8.

151. Koontz KL, Slifer KJ, Cataldo MD, Marcus CL. Improving pediatric compliance with positive airway pressure therapy: The impact of behavioral intervention. Sleep 2003;26:1010-5.

152. Pavone M, Verrillo E, Caldarelli V, Ullmann N, Cutrera R. Non-invasive positive pressure ventilation in children. Early Hum Dev 2013;89 Suppl 3:S25-31.

153. Teschler H, Stampa J, Ragette R, Konietzko N, Berthon-Jones M. Effect of mouth leak on effectiveness of nasal bilevel ventilatory assistance and sleep architecture. Eur Respir J 1999;14:1251-7.

154. King MS, Xanthopoulos MS, Marcus CL. Improving positive airway pressure adherence in children. Sleep Med Clin 2014;9:219-34.

155. Pépin JL, Leger P, Veale D, Langevin B, Robert D, Lévy P. Side effects of nasal continuous positive airway pressure in sleep apnea syndrome. Study of 193 patients in two French sleep centers. Chest 1995;107:375-81.

156. Massie CA, Hart RW, Peralez K, Richards GN. Effects of humidification on nasal symptoms and compliance in sleep apnea patients using continuous positive airway pressure. Chest 1999;116:403-8.

157. Kirk VG, O'Donnell AR. Continuous positive airway pressure for children: A discussion on how to maximize compliance. Sleep Med Rev 2006;10:119-27.

158. Li KK, Riley RW, Guilleminault C. An unreported risk in the use of home nasal continuous positive airway pressure and home nasal ventilation in children: Mid-face hypoplasia. Chest 2000;117:916-8.

159. Roberts SD, Kapadia H, Greenlee G, Chen ML. Midfacial and dental changes associated with nasal positive airway pressure in children with obstructive sleep apnea and craniofacial conditions. J Clin Sleep Med 2016;12:469-75.

160. Moeller JL, Paskay LC, Gelb ML. Myofunctional therapy. Sleep Med Clin 2014;9:235-43.

161. Lee SY, Guilleminault C, Chiu HY, Sullivan SS. Mouth breathing, "nasal disuse," and pediatric sleep-disordered breathing. Sleep Breath 2015;19:1257-64.

162. Guilleminault C, Huang YS, Monteyrol PJ, Sato R, Quo S, Lin CH. Critical role of myofascial reeducation in pediatric sleep-disordered breathing. Sleep Med 2013;14:518-25.

163. Villa MP, Brasili L, Ferretti A, Vitelli O, Rabasco J, Mazzotta AR, *et al.* Oropharyngeal exercises to reduce symptoms of OSA after AT. Sleep Breath 2015;19:281-9.

Pediatric Obstructive Sleep Apnea: A Short Review of Clinical Aspects

Christian Guilleminault[1], Yu-Shu Huang[2]

[1]Division of Sleep Medicine, Stanford University, Redwood City, CA, USA, [2]Child Psychiatry and Sleep Medicine, Chang Gung Memorial Hospital and Medical College, Linkou, Taiwan, ROC

Abstract

This report reviews the historical developments leading to recognition of pediatric obstructive sleep apnea. It briefly summarized the rationale why the upper airway becomes at risk of collapsibility during sleep. It also reviews the complaints that vary with age. It emphasizes points of the examination that must be systematically look for. The report reviews the variables to monitor, to look for, and to be analyzed, and patterns not often looked at but that disturb sleep and lead to complaints and symptoms in sleep polysomnography.

Keywords: Clinical evaluation, complaints, flow limitation, obstructive sleep apnea, pediatrics, polysomnography

INTRODUCTION

Sleep-disordered breathing (SDB) involved a decrease in the lumen of the upper airway (UA) during sleep. Historically, this decrease was noted to occur a variable degree overtime, based on the instrument used to investigate this decrease. Initially, respiration during sleep in children was monitored during sleep using nasal and oral prongs or thermistors, thoracic and abdominal strain gauge, calibrated esophageal pressure (Pes), Water™ ear oximeter, finger plethysmography, thoraco-diaphragmatic electromyography (Dia-EMG), and a neck "microphone" that did not measure decibel but power of UA sounds. In specific research cases, a tightly placed facial mask with a pneumotachograph was used, allowing measurements of tidal volume, expired CO_2, proper timing of inspiration time (Ti) expiration time (Te), and variable degree of airflow limitation with or without arterial line placed that allowed continuous monitoring of blood pressure and to intermittently draw arterial blood for blood gases measurements. These respiratory parameters were those used historically for the description of sleep apnea in children. The monitoring of Pes allowed one to accurately describe when there was a decrease in respiratory effort or an increase of such effort. The "dia"-EMG gave a similar indication but was not exactly quantifiable. The nonresearch montage used on all children seen at the Stanford University Sleep-disordered Clinic allows diagnosis of children "apnea"-complete cessation of air exchange at nose and mouth

and hypopnea, a partial cessation of air, exchange at nose and mouth. The oximeter indicates a drop of oxygen saturation. The Pes indicated if there was an increase or decrease in effort in association of the abnormal breathing pattern, and based on the recording, an "obstructive" or "diaphragmatic" (called by others "central") was scored. Simultaneously, sleep/wake markers 3 (electroencephalography [EEG] leads), chin muscle EMG, eye movements (2 leads), and one electrocardiographic leads were monitored, allowing recognition of sleep stages and wakefulness and also changes in autonomic nervous system (ANS) activity using plethysmography and heart rate recordings. These recordings led to the report of "obstructive sleep apnea (OSA) in children" and in infants.[1-3] The usage of the full face mask with pneumotachograph and Pes indicated that abnormal breathing during sleep was not limited to the above patterns and that there was in some children presence of a limitation of airway flow with increase in effort without evidence of drop in oxygen saturation. This was called "obstructive breathing," and it was reported to be seen frequently with snoring and disturbance of the sleep EEG.[4] When the pattern was verified by many, the term "Respiratory

Address for correspondence: Prof. Christian Guilleminault,
Division of Sleep Medicine, Stanford University, 450 Broadway Street,
MC 5704, Redwood City, CA 94063, USA.
E-mail: cguil@stanford.edu

Access this article online

Quick Response Code:

Website:
www.prccm.org

DOI:
10.4103/prcm.prcm_7_17

Related Respiratory Arousal (respiratory event related arousal [RERA])" was applied in the mid-1990s.[5] By that time, efforts were made to replace the thermistors/thermocouples that measured change in temperature but not change in flow by more sophisticated equipment. The laboratory of Rapoport in New York was very much involved in this development. Hosselet *et al.* in 1998 demonstrated that a nasal cannula/pressure transducer system[6,7] could provide a noninvasive indicator of flow limitation that can identify periods of elevated UA resistance both in normal participants and those with SDB, and the equipment was recommended as the valid standard for monitoring of nasal breathing in 2000. "Flow Limitation" was calculated as a percentage of total sleep time. Instead of recording nasal cannula, some authors monitored end-tidal CO_2 or tried to monitor both signals after 1992, but such double recording was shown to be difficult. With the improvement of transcutaneous CO_2 ($TcCO_2$) monitoring, such recording has been common after 2000.

Duration of events monitored during sleep was adjusted to age; abnormal obstructive breathing was scored if events lasted longer than two breaths (i.e., 3 breaths); in neonates, such duration was 3 s, at 12 months 6 s, and older age 10 s.[3]

Most of the descriptions of abnormal breathing are back to these historical descriptions. If Pes is uncommonly monitored today, noninvasive nasal cannula pressure transducer is the norm as it is $TcCO_2$ monitoring. Such montage has eliminated the possibility to score "central hypopnea" as "effort" cannot be monitored with nasal cannula but only with Pes.

The Upper Airway and Sleep

The pharynx is a collapsible tube, unlike lower airways, it has no rigid support, and the skeletal muscles and soft tissues support nonrespiratory functions: sucking, swallowing, vocalization/phonation, etc. However, the physiology during wakefulness is different from sleep; sleep causes fundamental modifications of pharyngeal muscle tone and reflex responses and can lead to narrowing and increased UA resistance in normal individuals. Muscle tone decreases during sleep and its decrease will be different during nonrapid eye movement (NREM) sleep and rapid eye movement (REM) sleep when it will be more significant. Also there is a greater risk of UA increased resistance at end inspiration during sleep: During wakefulness the decrease in lung inflation and decrease in lower airway size, normally induce a reflex that increases the tonic activation of the UA muscles, but this reflex is decrease during NREM sleep and is inactive during REM sleep.

The UA can be modelled using fluid dynamics physics, Experimentally, normal participants treated with subatmospheric nasal pressure develop OSA. Each individual has a critical pressure (Pcrit) or intrinsic collapsibility and a level of pharyngeal muscle activity that stiffens and enlarges the airway.[8,9] Experimentally normal participants treated with subatmospheric pressure develop OSA at a variable point: Some

subjects have a Pcrit at an atmospheric pressure level and will have a greater of UA collapse if the pressure during expiration goes below their Pcrit as subatmospheric pressure will develop during this phase of the respiratory cycle. Moreover, normally subatmospheric pressure in the UA causes reflex activation of nose and palate dilators (alai nasi, palatoglossus, levator/tensor palatini), oral pharynx/hyoid (genioglossus, geniohyoid, sternohyoid, sternothyroid), and larynx (cricoarytenoid and cricothyroid) – both tonic and respiratory cycled, but this reflex decreases and disappears during sleep, maximum during REM sleep but marked during NREM sleep.

Different factors may play a role in increasing the risk of collapsibility during sleep. Some of these factors involve the neuromuscular control of the UA and the complicated reflex loops involved in this control, and we are lacking information on this aspect particularly during sleep.

There are factors that are "nonsleep" related and that have been studied in the recent time, they are "external factors" that impact on the size of UA, particularly when located retropalatal and retroglossal. These external factors can be influenced by genetic and environmental factors and four factors have been identified: (a) bone structures (oral-facial bones), (b) infiltration of soft tissues - major factor being fat and fat at infiltration of UA is associated with central obesity leading to chest bellows impairment and complex respiratory-ventilatory problem, (c) leukotriene, and (d) inflammation arising from abnormal breathing during sleep.

Summary of Clinical Evaluation

During clinic visits, children must have a pediatric evaluation including body mass index (BMI), vital signs, and neck circumference measurements.[10] The pediatric sleep questionnaire[11] is commonly used.

Complaints will vary with age as follows:

Infants
Disturbed nocturnal sleep with repetitive crying, poorly established day/night cycle, noisy breathing or snoring, nocturnal sweating, poor suck, absence of normal growth pattern, or failure to thrive, observation of apneic events, report of apparent life-threatening event, and presence of repetitive earaches or upper respiratory infection (URI).

Toddlers
Noisy breathing or snoring, agitated sleep or disrupted nocturnal sleep, crying spells or sleep terrors, grouchy and/or aggressive daytime behavior, daytime fatigue, nocturnal sweating, mouth breathing, poor eating or failure to thrive, repetitive URI, and witnessed apneic episodes.

Preschool children
Regular, heavy snoring, mouth breathing, drooling during sleep, agitated sleep, nocturnal awakenings, confusional arousals, sleepwalking, sleep terrors, nocturnal sweating, abnormal sleeping positions, and persistence of bedwetting;

abnormal daytime behavior and aggressiveness; hyperactivity; inattention, daytime fatigue, and hard to wake up in the morning; and morning headache, increased need for napping, compared with peers, poor eating, growth problems, and frequent URI.

School children

Regular, heavy snoring; agitated sleep; abnormal sleeping positions; insomnia; delayed sleep phase syndrome; confusional arousal; sleepwalking; sleep talking; persistence of bedwetting; nocturnal sweating; hard to wake up in the morning; mouth breathing; drooling; morning headache; daytime fatigue; daytime sleepiness with regular napping; abnormal daytime behaviors/pattern of attention-deficit/hyperactivity disorder; aggressiveness; abnormal shyness, withdrawn and depressive presentation; learning difficulties; abnormal growth patterns; delayed puberty; repetitive URI; and dental problems such as a crossbite, malocclusion (Class II or III), and small jaw with overcrowding.

Evaluation

The suspicion of SDB indicates the need not only for a general pediatric evaluation but also for a thorough evaluation of the UA anatomy.

Starting with the nose, one should look for asymmetry of the nares, a large septal base, collapse of the nasal valves during inspiration, presence of a deviated septum, or enlargement of the inferior nasal turbinates.

Next, the oropharynx should be examined for the position of the uvula in relation to the tongue. Presence of a short lingual frenulum using Kotlow measurement and Queiroz Marchesan scale,[12,13] much more common than a short nasal frenulum.[14] The scale developed by Mallampati et al. reviewed by Friedman et al.[15] may help evaluating the narrowness of the upper airway. There should be systematic search for missing teeth questioning subject and parents and requesting if necessary help of pediatric dentist with performance of specific X-rays (Panorex).[16] The size of the tonsils should be compared with the size of the airway; application of a standardized scale is useful.[17] The presence of a high and narrow hard palate, overlapping incisors, a crossbite, and an important (>2 mm) overjet (the horizontal distance between the upper and lower teeth) are indicative of a small jaw and/or abnormal maxillomandibular development.[18]

This clinical evaluation provides important details of the UA anatomy and identifies anatomical risk factors that can predispose one to the development of abnormal breathing. The results of this examination must be summarized as the different anatomical narrowings have additive effects. The apparent sizes of tonsils and adenoids are not the only anatomical findings that determine whether or not SDB is present. A change in flow due to an abnormal nose, secondary development of turbulence, and the increased collapsibility at specific vulnerable points in the UA are elements to consider.

RECORDING SLEEP-DISORDERED BREATHING

Testing during sleep is the only way to confirm the presence of SDB. Controversy exists concerning the need for and type of test to be performed. Polysomnography (PSG) is described above, and its results are considered as the most accurate. Home study will have less reliability than laboratory studies, but if performed, home studies should have sleep/wake monitoring.

Compared to PSG, nocturnal polygraphy has been performed; it usually involves monitoring of a limited number of the respiratory leads, particularly nasal cannula and oxygen saturation; usually an EEG lead is also monitored. This monitoring device can confirm the presence of abnormal breathing during sleep, but if study is negative, the study cannot affirm the absence of breathing problem during sleep.

An increase in respiratory efforts is associated with changes in ANS settings as measured by nocturnal polygraphic arterial tonometry or pulse transit time (PTT).

These changes will affect the cardiovascular system: In an individual with normal autonomic-nervous-system –ANS-, two types of responses can be seen when an increase in respiratory effort occurs during sleep: activation or arousal with cortical involvement. Activation is related to the recruitment of sensory inputs that will lead to a polysynaptic motor response after relay of sensory input in the brainstem and subcortical structures. An ANS response may be seen with brainstem reflexes leading to full reopening of the UA without EEG cortical arousal, or it may be seen as the consequence of an EEG cortical arousal.

The presence of cortical arousals will be associated with clinical symptoms such as complaints of excessive daytime somnolence, irritability, or unrefreshing sleep. The role of repetitive "activation" is unknown in children. Some ambulatory equipment's recognition of SDB is based on ANS responses, using algorithms, commonly associating results of heart rate, and finger plethysmography analyses. The algorithms are proprietary and undisclosed. Such equipment identifies nocturnal sleep disruption, together with monitoring of oxygen saturation and has been considered to provide information equivalent to those obtained with the limited home recordings.

Recording of variables such as pulse-transit-time-PTT-provided by a device using changes in ANS, cannot be used to recognize abnormal breathing during sleep, but recording of "PTT" may be performed in association with other variables during sleep. As a research tool, it has been used in association with PSG to indicate changes in ANS status with identification of sympathetic activation.

Nocturnal oximetry

This is the simplest type of continuous recording. It does not recognize sleep and wakefulness but may indicate the validity of treatment, particularly positive airway pressure or evidence of abnormal repetitive hypoxemic events during the nocturnal period.

Continuous transcutaneous CO_2 monitoring

For a long time, long-term $TcCO_2$ monitoring was considered unreliable, this is not true anymore, but need for change in placement of electrode, need for calibration, and recalibration if sensor is moved are the limitations. This recording may be more helpful in some specific conditions, particularly in children with hypoventilation during sleep related to any cause. If it is not a diagnostic tool in isolation, it may be helpful to follow treated patient at home.

Scoring polysomnography

By 12 months of age, sleep EEG is well developed, and scoring sleep using the Rechtschaffen and Kales criteria and the AASM criteria for short arousal are easy.[19-21]

Furthermore, respiratory rate (RR) is relatively steady from 2 years on between 16 and 18 breaths/min for Stages 2–4 of NREM sleep 17 and 19 breaths/min during REM sleep.

Defining a respiratory event

Event begins at the start of inspiration of the first abnormal breath. If the start of the inspiration is not detectable (such as incomplete apnea or central apnea), the respiratory event will start at the end of expiration of the last detected breath before the abnormal respiratory event. It ends at the start of inspiration of the breath following the abnormal respiratory event.

Definition used

Apnea[20] is more than 90% fall in airflow at the nose and mouth for longer than 2 breaths, independent of oxygen desaturation, change in EEG, or stages of sleep. It is subdivided in central, mixed and obstructive based on airflow and inspiratory efforts.

Hypopnea

An hypopnea[20,21] is a breathing event lasting at least longer than 2 breaths (i.e., 3 breaths) independent of age of the child (1–18 years). It is scored based on nasal cannula pressure transducer (scoring without esophageal manometry); it is associated with a decrease of the curve by 30% compared to the 3 min prior baseline recording. An hypopnea begins with the drop of the nasal cannula curve to reach a 30% drop during one breath. The hypopneas end when the nasal cannula returns to baseline. The duration of the hypopneas is calculated from the inspiratory movement of the first abnormal breath till the inspiratory movement of the first normal breath.

Stanford adjustment rule

This first breath associated with the arousal may show indication of increased movement amplitude above prior baseline volume and associated with short-lived hyperventilation. If there is more than 1 breath during the arousal period (i.e., at least two successive breaths are required to perform a comparison), the drop in amplitude preceding the arousal may be calculated compared to the breaths associated with the arousal.[22]

Investigation of other respiratory signals should be performed for the breaths involved in the hypopneas: (1) checking presence/absence of increase in inspiratory muscle EMG simultaneously with movement and change in amplitude of the inductive thoracic and/or abdominal belts; such association indicates the presence of obstructive hypopneas. If there is a decrease in all of the above signals during hypopneas, "central hypopneas" as seen in association with phasic events of REM sleep may be suspected but cannot be affirmed without Pes recording.

Obstructive hypopnea

The definition is based on nasal pressure transducer; discernable reduction in the baseline signal amplitude for >2 breaths (3 or more breaths) with persistent respiratory effort associated with an EEG arousal or with oxygen desaturation.

The EEG pattern can be associated with a change of the plethysmographic curve with a visually recognizable descending and short-lived curve pattern indicative of a sympathetic activation. Sympathetic activation cannot per se indicate EEG arousal as "sympathetic activation," i.e., stimulation at brainstem but stopped by thalamic gate may occur. However, "sympathetic activation may help recognizing EEG arousals."

Hypopnea with usage of esophageal pressure

Pes makes recognition of hypopnea and other abnormal breathing patterns easier. Pes helps in recognition of hypopnea onset with a change in Pes amplitude compared to prior recorded breaths and allows quantifying (after Pes calibration) the amount of change in inspiratory effort associated with each breath. Patterns such as "Pes crescendos," "sustain continuous effort," and "Pes reversal" are systematically looked for. (a) Pes crescendo: sequence of four or more breaths that show increasingly negative peak end inspiratory pressure seen with Pes. (b) Continuous sustained respiratory effort: Definition: repetitive, abnormally negative peak end-inspiratory Pes ending at the same negative inspiratory pressure without a crescendo pattern. It is associated with continuous airflow limitation on nasal cannula pressure transducer signal. Pes allows defining hypopneas with a decreased effort (such as seen in REM sleep).[23-25]

OTHER PATTERNS OF ABNORMAL BREATHING
Flow limitation

Evaluation with nasal cannula pressure transducer allows recognition of flow limitation. Definition: flattening of the peak of the nasal cannula pressure transducer wave contour, **o**r change in the normal round presentation of the peak of the nasal cannula. It is very often but not always associated with changes in Pes recording (and a change in Pes may not be associated with a pattern of flow limitation). It is also often associated with snoring. It may involve one or several breaths. It is not associated with a 3% or 4% SaO_2 drop. The "time spent in flow limitation" is the calculated variable. At least four successive breaths must be associated with abnormal wave contour. The

duration of flow limitation is calculated from the time of the start of flattening to the time when the wave contour normalizes or returns to baseline. The report indicates the total time of flow limitation from total sleep time and the longest episode of flow limitation (in minute and second).[26,27] Systematic usage of Pes indicates that flow limitation is associated with systematic increase in inspiratory effort. Flow limitation is associated with abrupt EEG changes that have been described using a different EEG scoring system called the "cyclic alternating pattern" (CAP) scoring system [Figure 1].[28]

Respiratory event-related arousals

Historically, it was defined before flow limitation, and it was related initially to snoring sound and EEG arousal. It is a sequence of breaths ≥10 s characterized by increasing respiratory effort or flattening of the nasal pressure waveform it terminates with an arousal from sleep, and the sequence does not meet criteria for AASM apnea or hypopnea. The major difference with definition of "flow limitation" is that RERAs count only one event at the end of flow limitation period that ends with a 3 s EEG arousal. Studies of "flow limitation"[26,27] have shown that if "arousal" is scored with a different definition, there are more sleep disturbances - the cause of complaints, signs, and comorbidities - than when just RERAs are scored. However, usage of the CAP[28] that scored an EEG arousal with much shorter EEG changes (i.e., phase A2 of CAP system), or usage of fast Fourier Transform to analyze EEG with a 1 s window have shown that there were more sleep disturbances than when scoring "arousal EEG" lasting 3 s while the cortex react in 300 milliseconds; "flow limitation" may be a better approach but more normative data are needed [Figure 2].


Figure 1: Inspiratory flow limitation. Example of a recording of "inspiratory flow limitation" as indicated by the monitoring of nasal airflow through the "nasal cannula-pressure transducer." No apnea or hypopnea is present in the segment, but the sleep EEGs (4 channels-1-4 from top) indicate the presence of cyclic alternating pattern phase A2, indicative of NREM sleep disturbances. The recording of the nasal cannula measuring airflow exchange is presented on channel 14 from top The figure shows the presence of flow limitation with the presence of an abnormal wave contour: instead of a smooth round wave contour, there is a truncation of the wave contour during inspiration (per convention; up part of the wave), there is no mouth breathing (oral thermistor - channel 15 from top), and chest and abdomen inductive plethysmography bands are indicating breathing efforts. The figure shows a worsening of the flow limitation from left to right with decrease in amplitude of the wave. This worsening is associated with the occurrence of snoring (channel 13 from top). However, with onset of snoring, there is another event occurring: nasal cannula-pressure transducer is an unreliable way to measure expiratory flow, and if an expiratory flow limitation occurs a different variable must be monitored. Normally expiration is mostly "passive" with the absence of involvement of expiratory muscles (monitored on channel 19 from top-bottom channel) as can be seen there is the appearance of "active" contraction of expiratory muscles as seen on the right of the figure. There are simultaneous changes in the inspiratory wave contour with reduction of its amplitude and appearance of expiratory efforts. The oxygen saturation (channel 11 from top) changes somewhat with SaO$_2$ going from 94% to 93%, but this 1% change is not a change monitored in any international atlas. Channel 12 monitors the finger photoplethysmography, i.e., the finger vaso-constriction, per convention the curve is presented such as an increase in vasoconstriction indicative of sympathetic activation is associated with a downward displacement of the curve. As can be seen in association with occurrence of snoring and other flow changes, there is a change of the photoplethysmography curve indicative of repetitive stimulation of the sympathetic nerve with snoring, and with swings of the photoplethysmography more pronounced at the right of the figure indicative of a larger stimulation of the sympathetic tone associated with worsening of inspiratory and expiratory flow limitation. None of these changes are taken into consideration in the international scoring manuals looking at abnormal breathing during sleep, despite the fact that many disruptions occur and worsen with snoring.

Figure 2: Example of abnormal increased inspiratory effort measured with esophageal manometry [Pes = esophageal pressure]. This recording present 15 min of continuous recording. Fourteen channels of the recording have been selected for presentation of the figure from top to bottom. Electroencephalography, Chin electromyography, 2 eye movements, finger photoplethysmography (with sympathetic activation toward the bottom of figure), 2 leg electromyography, pulse oximetry with saturation reading, snore indicated by neck microphone measuring power, nasal cannula-pressure transducer wave contour, chest and abdomen plethysmographic bands, and esophageal manometry recording (bottom). Esophageal pressure has been calibrated before the beginning of recording. The negative peak is per convention placed toward the bottom of the recording. The end of the recording probe is placed in the lower esophagus. This segments of recording show a progressive increase in inspiratory efforts with peak esophageal pressure becoming more and more negative during the following 10 min. There is the presence of inspiratory flow limitation when looking at the nasal cannula wave contour, but no change indicating increase in effort. The electroencephalography analysis indicates the presence of cyclic alternating pattern phase A2, but a clear electroencephalography arousal is only noted at the end of the recording in association with return to normal breathing and important chin electromyography discharge. The investigation of the photoplethysmography indicates that during the entire segment, there are clear indications of several episodes of sympathetic activation that correlate with the cyclic alternating pattern phase A2 bursts, but these short arousals are not sufficient to lead to reopen the airway. A respiratory event- related arousal will be scored at the end of the event in association with the more than 3 s electroencephalography arousal, but the scoring will ignore the long abnormal breathing segment, the calculation of the "flow limitation" gives a better view of the duration and amount of disturbance than calculation of the respiratory -related arousal, moreover "respiratory event related arousals" are not taken into consideration when the apnea-hypopnea index is calculated, the figure indicates the limitations of many scoring systems.

Tachypnea

Definition

An increase in RR above that seen during quiet unobstructed breathing: by a minimum of 3 breaths/min in NREM sleep or 4 breaths/min in REM sleep for ≥30 s. After 24 months of age, normal RR is 16–18 breaths/min in NREM sleep and 17–19 breaths/min in REM sleep. No associated changes in oxygen saturation, Pes, or EEG are required. It is based on the definition: Tv × RR = minute ventilation. If the RR increase and oxygen saturation stay stable, this indicates a compensation for decrease in tidal volume and indication of abnormal breathing during sleep.

Mouth breathing

Studies on mouth breathing have shown that normal controls usually spend 4% of total sleep time with mouth breathing, and studies in children showed a maximum amount of mouth breathing of 10% of total sleep time.[29-31] Mouth opening is associated with a backward and downward displacement of the mandible and the tongue and has been shown to increase the propensity to UA collapse.[32] posterior and inferior movement of the mandible may shorten the UA dilator muscles located between the mandible and hyoid and compromise their contractile force by producing unfavorable length/tension relationships in these muscles. One explanation for this phenomenon is that jaw opening is associated with a posterior movement of the angle of the jaw, which compromises the oropharyngeal airway diameter. Open mouth breathing is associated with an increase in pharyngeal length. The faster airflow generated by the longer and narrower UA may increase the negative intraluminal pressure during inspiration and facilitate collapse of the UA.

Conclusion

We have learned a large amount about SDB over time. We know that certain groups of children are at greater risk of abnormal breathing during sleep; including obese children,

when an increase of BMI by 1 kg/m^2 above the upper limit of normal is associated with a 12% increase in risk for OSA, and children born prematurely,[33] and as mentioned above change in oral-facial growth that will begin with birth. this growth change may be related not only to genetic factors (such as those involved in teeth development or oral development) but also to environmental factors, particularly involving functions such as sucking, swallowing, speech development, and nasal breathing.[34,35] UA allergies with impact on normal breathing and leading to increase in local inflammatory factors have also been considered risk factors. The frequency of SDB related to UA collapse during sleep has oscillated; initially, it was considered as low as 2%–4% of the general population, but with better recognition of the abnormal breathing during sleep, frequency increased; currently, a conservative estimate would be 7%, but some studies go to a frequency as high as 11% of the general children population. Moreover, there is an agreement that certain ethnic groups are at greater risks. more particularly, African-American and their tendency to increase BMI more frequently than Caucasians (and the role of socioeconomic factors have not been well identified) and Far East Asian with the very different orientation of the maxilla at birth compared to Caucasians. However, the main issue is to recognize children with abnormal breathing as early as possible and to know how to give value to indicators seen in testing.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

REFERENCES

1. Guilleminault C, Eldridge FL, Simmons FB, Dement WC. Sleep apnea in eight children. Pediatrics 1976;58:23-30.
2. Guilleminault C, Ariagno R, Souquet M, Dement WC. Abnormal polygraphic findings in near-miss sudden infant death. Lancet 1976;1:1326-7.
3. Guilleminault C, Ariagno R, Korobkin R, Nagel L, Baldwin R, Coons S, et al. Mixed and obstructive sleep apnea and near miss for sudden infant death syndrome: 2. Comparison of near miss and normal control infants by age. Pediatrics 1979;64:882-91.
4. Guilleminault C, Winkle R, Korobkin R, Simmons B. Children and nocturnal snoring: Evaluation of the effects of sleep related respiratory resistive load and daytime functioning. Eur J Pediatr 1982;139:165-71.
5. Guilleminault C, Pelayo R, Leger D, Clerk A, Bocian RC. Recognition of sleep-disordered breathing in children. Pediatrics 1996;98:871-82.
6. Norman RG, Ahmed MM, Walsleben JA, Rapoport DM. Detection of respiratory events during NPSG: Nasal cannula/pressure sensor versus thermistor. Sleep 1997;20:1175-84.
7. Hosselet JJ, Norman RG, Ayappa I, Rapoport DM. Detection of flow limitation with a nasal cannula/pressure transducer system. Am J Respir Crit Care Med 1998;157(5 Pt 1):1461-7.
8. Marcus CL, McColley SA, Carroll JL, Loughlin GM, Smith PL, Schwartz AR. Upper airway collapsibility in children with obstructive sleep apnea syndrome. J Appl Physiol 1994;77:918-24.
9. Marcus CL, Katz ES, Lutz J, Black CA, Galster P, Carson KA. Upper airway dynamic responses in children with the obstructive sleep apnea syndrome. Pediatr Res 2005;57:99-107.
10. Sinha D, Guilleminault C. Sleep disordered breathing in children. Indian J Med Res 2010;131:311-20.
11. Chervin RD, Hedger K, Dillon JE, Pituch KJ. Pediatric sleep questionnaire (PSQ): Validity and reliability of scales for sleep-disordered breathing, snoring, sleepiness, and behavioral problems. Sleep Med 2000;1:21-32.
12. Kotlow LA. Ankyloglossia (tongue-tie): A diagnostic and treatment quandary. Quintessence Int 1999;30:259-62.
13. Queiroz Marchesan I. Lingual frenulum: Classification and speech interference. Int J Orofacial Myology 2004;30:31-8.
14. Guilleminault C, Huseni S, Lo L. A frequent phenotype for paediatric sleep apnoea: Short lingual frenulum. ERJ Open Res 2016;2. pii: 00043-2016.
15. Friedman M, Ibrahim H, Bass L. Clinical staging for sleep-disordered breathing. Otolaryngol Head Neck Surg 2002;127:13-21.
16. Guilleminault C, Abad VC, Chiu HY, Peters B, Quo S. Missing teeth and pediatric obstructive sleep apnea. Sleep Breath 2016;20:561-8.
17. Friedman M, Tanyeri H, La Rosa M, Landsberg R, Vaidyanathan K, Pieri S, et al. Clinical predictors of obstructive sleep apnea. Laryngoscope 1999;109:1901-7.
18. Kim JH, Guilleminault C. The nasomaxillary complex, the mandible, and sleep-disordered breathing. Sleep Breath 2011;15:185-93.
19. Rechtschaffen A, Kales A, editors. A Manual of Standardized Terminology, Techniques and Scoring Systems for Sleep Stages of Human Subjects. Los Angeles: BIS/RRI, UCLA; 1968.
20. Iber C, Ancoli-Israel S, Chesson AL Jr., Quan SF, for the American Academy of Sleep Medicine. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications. Version 2.0. Darien, Illinois: American Academy of Sleep Medicine; 2012. Available from: http://www.aasmnet.org. [Last accessed on 2017 May 20].
21. Bonnet M, Carley D, Carskadon M, Easton P, Guilleminault C, Harper R, et al. ASDA report. EEG arousals: Scoring rules and examples: A preliminary report from the sleep disorders Atlas Task Force of the American Sleep Disorders Association. Sleep 1992;15:173-84.
22. Lin CH, Guilleminault C. Current hypopnea scoring criteria underscore pediatric sleep disordered breathing. Sleep Med 2011;12:720-9.
23. Guilleminault C, Khramtsov A. Upper airway resistance syndrome in children: A clinical review. Semin Pediatr Neurol 2001;8:207-15.
24. Guilleminault C, Li K, Khramtsov A, Palombini L, Pelayo R. Breathing patterns in prepubertal children with sleep-related breathing disorders. Arch Pediatr Adolesc Med 2004;158:153-61.
25. Guilleminault C, Lee JH, Chan A. Pediatric obstructive sleep apnea syndrome. Arch Pediatr Adolesc Med 2005;159:775-85.
26. Palombini LO, Tufik S, Rapoport DM, Ayappa IA, Guilleminault C, de Godoy LB, et al. Inspiratory flow limitation in a normal population of adults in São Paulo, Brazil. Sleep 2013;36:1663-8.
27. Arora N, Meskill G, Guilleminault C. The role of flow limitation as an important diagnostic tool and clinical finding in mild sleep-disordered breathing. Sleep Sci 2015;8:134-42.
28. Terzano MG, Parrino L, Sherieri A, Chervin R, Chokroverty S, Guilleminault C, et al. Atlas, rules, and recording techniques for the scoring of cyclic alternating pattern (CAP) in human sleep. Sleep Med 2001;2:537-53.
29. Fitzpatrick MF, Driver HS, Chatha N, Voduc N, Girard AM. Partitioning of inhaled ventilation between the nasal and oral routes during sleep in normal subjects. J Appl Physiol 2003;94:883-90.
30. Fitzpatrick MF, McLean H, Urton AM, Tan A, O'Donnell D, Driver HS. Effect of nasal or oral breathing route on upper airway resistance during sleep. Eur Respir J 2003;22:827-32.
31. Lee SY, Guilleminault C, Chiu HY, Sullivan SS. Mouth breathing, "nasal disuse," and pediatric sleep-disordered breathing. Sleep Breath 2015;19:1257-64.
32. Lee SH, Choi JH, Shin C, Lee HM, Kwon SY, Lee SH. How does open-mouth breathing influence upper airway anatomy? Laryngoscope 2007;117:1102-6.
33. Huang YS, Paiva T, Hsu JF, Kuo MC, Guilleminault C. Sleep and breathing in premature infants at 6 months post-natal age. BMC Pediatr 2014;14:303.
34. Huang YS, Guilleminault C. Pediatric obstructive sleep apnea and the critical role of oral-facial growth: Evidences. Front Neurol 2013;3:184.
35. Guilleminault C, Akhtar F. Pediatric sleep-disordered breathing: New evidence on its development. Sleep Med Rev 2015;24:46-56.

Viruses and Hospitalization for Childhood Lower Respiratory Tract Infection in Malaysia: A Prospective Study

Anna Marie Nathan[1,2], Yun Lee Qiao[3], Faizatul Lela Jafar[4], Yoke-Fun Chan[4], Kah Peng Eg[1,2], Surendran Thavagnanam[1,2], Sazaly Abu Bakar[4,5], I-Ching Sam[4], Jessie Anne deBruyne[1,2]

Departments of [1]Paediatrics and [4]Medical Microbiology, University Malaya Medical Centre, [2]University Malaya Paediatric and Child Health Research Group, University of Malaya, [5]Tropical Infectious Diseases Research and Education Centre, Kuala Lumpur, [3]Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia

Abstract

Context: Viruses are the main causes of acute lower respiratory tract infections (ALRIs) in childhood and its impact on hospital admission is largely unknown. **Aims:** The aim of this study is to determine (a) virus detection, (b) risk factors for admission, particularly virus detection, and (c) differential clinical responses to viral infections, in children attending pediatric emergency department (PED) with an ALRI in Malaysia. **Subjects and Methods:** This prospective study included children ≤2 years who presented to PED between September 1, 2010, and March 6, 2012, with features of lower respiratory tract infection. Nasopharyngeal aspirates (NPAs) were tested using a multiplex polymerase chain reaction (PCR) for 11 respiratory viruses. **Results:** Two hundred children were recruited in the study. Two-thirds (65.5%) of them were admitted. NPA-PCR was positive in 54% of all patients: 50.4% of those admitted and 60.9% of those discharged. The most common viruses detected were respiratory syncytial virus (RSV) (49.1%), rhinovirus (30.6%), and parainfluenza viruses (12.0%). Five patients had mixed infections. RSV detection was associated with previous history of wheeze (odds ratio, 2.05 [95% confidence interval 1.06, 4.00]). Viruses were detected in all severely ill patients and patients with apnea. Multivariate analysis showed that virus detection was not associated with the need for admission, but female sex, lack of breastfeeding and, attending nursery were associated with hospitalization. **Conclusions:** Half of the children who presented to the emergency room with ALRI had viruses detected in their NPA. There was no association between virus detection and hospitalization. RSV was associated with history of wheeze. Female gender, lack of breastfeeding, and nursery attendance were associated with hospitalization.

Keywords: Acute respiratory infections, etiology, bronchiolitis, children, emergency department, Malaysia, pneumonia, viruses

Introduction

Viruses are the main cause for acute lower respiratory tract infection (ALRI), whether in the developing or developed countries. Factors determining hospitalization are important for health and economic reasons. Many studies focus on etiology of ALRI in admitted patients,[1-3] but few studies focus on children attending the pediatric emergency department (PED) alone[4,5] to determine the factors associated with admission, especially positive virus detection and coinfections.

The aim of this study was to determine the risk factors for admission in children attending the PED with an ALRI.

Subjects and Methods

Ethics

Ethical approval was obtained from the hospital's Medical Ethics Committee (No. 996.3) and informed parental consent was obtained. However, no assent was obtained from patients aged above 7 years. Patients' information was anonymized and de-identified before analysis.

Study site

This study was conducted in a 1068-bedded tertiary general hospital in Kuala Lumpur, Malaysia, which serves an urban population of 1.7 million. In our center, we have 100 pediatric beds, including a 10-bed Pediatric Intensive Care Unit.

How to cite this article: Nathan AM, Qiao YL, Jafar FL, Chan YF, Eg KP, Thavagnanam S, *et al*. Viruses and hospitalization for childhood lower respiratory tract infection in Malaysia: A prospective study. Pediatr Respirol Crit Care Med 2017;1:46-51.

Study type and patient selection

This is a prospective study of children, 2 years old and younger, who presented to the PED, between September 1, 2010, and March 6, 2012, with ALRIs. ALRI was defined as symptoms (either cough or shortness of breath) and signs (wheeze and/or crepitation and/or recession and/or respiratory distress) of a lower respiratory tract infection. Children with a diagnosis of asthma and those attending the PED during the weekends were excluded from the study.

Data collection

Basic demographic data including comorbidities, birth history, concurrent medications, family history of asthma and atopy, antenatal and postnatal exposure of cigarette smoke, breastfeeding (total duration and exclusive), history of wheezing, current weight, presenting symptoms and signs, and outcome were collected prospectively, using a preprepared data collection sheet.

Specimen processing

All children had nasopharyngeal aspirates (NPAs) collected by trained nurses after nebulization of either 3% NaCl or salbutamol to enhance the chance of virus detection. The exact choice was at the discretion of the attending doctor samples being kept at −20°C before testing. RNA was extracted from 140 μl of each sample using QIAmp Viral RNA Mini Kit (QIAGEN, Germany) following the manufacturer's protocol and eluted in 50 μL of sterile water. Complementary DNA was synthesized using Superscript III RT (Invitrogen, USA). Each reaction was carried out with 0.25 μL of 20X reverse transcriptase-primer mix (500 μg/ml), 1 μl of dNTPs (10 mM each), and 3 μL of RNA template (1 μg/μL) and heated at 65°C for 5 min. The solution was equilibrated at 4°C and mixed with 1 μL of 5X first-strand buffer and 0.25 μL of 0.1 M DTT and incubated at 25°C for another 5 min. Finally, 0.25 μL (50 units) of Superscript II Reverse transcriptase was added to the solution with a final volume of 5 μL, which was then incubated at 50°C for 1 h, before inactivation at 70°C for 15 min. The final products were stored at −20°C until testing using a multiplex polymerase chain reaction (PCR) assay, RespiDetect (Tropical Infectious Diseases Research and Education Centre, Malaysia), following the manufacturers' protocol. This assay is based on dual-priming oligonucleotide technology and detects 11 respiratory viruses: respiratory syncytial virus (RSV), influenza A and B, parainfluenza virus 1–3, adenovirus, human metapneumovirus, human rhinovirus (HRV), coronavirus, and bocavirus. PCR products of the expected size were identified by gel electrophoresis.

Definitions of variables and outcomes

The main outcome measured was admission versus discharge as decided by the PED physician. Oxygen is usually supplied if the saturation is <95% in room air or if there are signs of respiratory distress. Each patient's weight was measured and computed into Z score using gender- and age-specific cutoff points proposed by the World Health Organization guidelines.[4]

Life-threatening pneumonia was defined as children who require intensive care treatment and/or noninvasive ventilatory support, for example, bilevel continuous positive airway pressure or high-flow nasal cannula oxygen. Low birth weight was defined as birth weight <2.5 kg. Prematurity was defined as gestation <37 weeks. Environmental tobacco smoke (ETS) exposure was defined as presence of any smoker in the family or caregiver's household.

Statistics

The data were analyzed using IBM Corp. Released 2011. IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp. Data were described using percentage, median, and interquartile range (IQR). The Chi-squared test or Fisher's exact test (where appropriate) was used to perform univariate analysis between the clinical factors and the outcome, i.e. hospitalization or not. Factors included in univariate analysis were as follows: age, gender, presence of any comorbidity (such as chronic lung disease, heart disease, and chronic liver and gut disease), family history of atopy, prematurity, birth weight, current weight percentile $<−2$ standard deviations, any breastfeeding, attending nursery or daycare, exposure to ETS (antenatal and postnatal), positive respiratory virus PCR result, and PCR positive for more than one virus. Binary logistic regression was performed with factors identified in univariate analysis with $P < 0.10$. In the final analysis of results, $P < 0.05$ was considered statistically significant. Association was presented as odds ratios (ORs) with 95% confidence intervals (CIs).

RESULTS

Altogether, 255 children were recruited in the study. Thirty-two NPAs were misplaced and 23 were excluded due to a possible asthma. Finally, 200 episodes of infection were analyzed [Figure 1].

Demographic data

Characteristics of the patients are shown in Table 1. The median age was 8 months with a male predilection. The ethnic distribution is representative of Malaysia. The main comorbid diseases in these children were previous pneumonia ($n = 21$, 58.3%) and cardiovascular disease ($n = 4$, 11.1%). The median (IQR) gestational age of the children who were premature was 34 weeks (33–35 weeks). There was a significant exposure to both antenatal and postnatal ETS exposure. More


Figure 1: Study flow.

Table 1: Demographic characteristics between those admitted versus discharged

Demographic characteristics	All children, *n* (%)	Admitted (*n*=131), *n* (%)	Discharged (*n*=69), *n* (%)	P	OR/Z score	95% CI
Age*						
Median (range), years	0.7 (0-2.3)	0.7 (0-2.3)	0.6 (0.1-1.7)	0.08	Z=−1.75	NA
Sex*						
Male	132 (66.0)	80 (6.01)	52 (75.4)	0.04	0.81	0.67-0.99
Female	68 (34.0)	51 (38.9)	17 (24.6)			
Ethnicity*						
Malay	170 (85.0)	117 (89.3)	53 (76.8)	0.04	-	-
Chinese	6 (3.0)	4 (3.1)	2 (2.9)			
Indians	22 (11.0)	10 (7.6)	12 (17.4)			
Others	2 (1.0)	0	2 (2.9)			
Comorbidities						
Yes	36 (17.5)	26 (19.8)	10 (14.5)	0.35	1.13	0.89-1.42
No		105 (80.2)	59 (85.5)			
Premature						
Yes	19 (9.5)	10 (76.9)	9 (13.0)	0.22	0.79	0.51-1.22
No		120 (23.1)	60 (76.0)			
Nursery*						
Yes	105 (52.5)	77 (59.2)	28 (41.2)	0.016	1.29	1.04-1.59
No		53 (40.8)	40 (58.8)			
Birth weight						
Median (IQR)	3.0 (2.8,3.3)	3.0 (2.8,3.3)	3.0 (2.7,3.3)	0.46	Z=-0.69	NA
Weight ≤−2SD						
Yes	37 (18.5)	27 (21.8)	10 (14.9)	0.23	1.16	0.92-1.46
No		97 (78.2)	57 (85.1)			
Family history of atopy						
Yes	59 (29.5)	37 (29.1)	22 (33.3)	0.55	0.83	0.43-1.58
No		90 (70.9)	44 (66.7)			
Environmental tobacco smoke						
Antenatal						
Yes	85 (43)	54 (41.5)	31 (46.3)	0.53	0.94	0.76-1.15
No		76 (58.5)	36 (53.7)			
Postnatal						
Yes	111 (55.5)	56 (43.1)	30 (43.5)	0.82	0.98	0.80-1.20
No		74 (56.9)	39 (56.5)			
Breastfeeding (any)*						
Yes	152 (76.9)	93 (72.7)	59 (88.1)	0.01	0.75	0.62-0.91
No		35 (27.3)	8 (11.9)			
Diagnoses*						
Bronchiolitis/others	138 (69)	81 (61.8)	57 (82.6)	0.002	0.34	0.16-0.69
Pneumonia	62 (31)	50 (38.2)	12 (17.4)			
PCR for viruses						
Positive	108 (54)	66 (50.4)	42 (60.9)	0.16	0.87	0.71-1.06
Negative	92 (46)	65 (49.6)	27 (39.1)			
PCR positive for >1 virus						
Yes	5 (2.5)	3 (2.3)	2 (2.9)	0.79	0.79	0.11-6.75
No	195 (87.5)	128 (87.7)	67 (87.1)			

*Significant at *P*<0.01 and included into the logistic regression analysis. OR: Odds ratio, PCR: Polymerase chain reaction, SD: Standard deviation, IQR: Interquartile range, CI: Confidence interval, NA: Not available

than two-thirds of the children (77%) were breastfed. The most common diagnosis was bronchiolitis (69%) and two-thirds of patients (65.5%) were admitted.

Pathogen detection

NPA-PCR was positive in 54% of children: 50.4% of those admitted (*n*=66/131) and 60.9% of those discharged (*n*=42/69). The NPA was positive in 52% (*n* = 72/138) of children with bronchiolitis and 58% (*n* = 36/72) of children with pneumonia. Common viruses detected were RSV (*n* = 53, 49.1%), rhinovirus (*n* = 33, 30.6%), and parainfluenza virus (*n* = 13,

12.0%) and altogether these represented 91.7% of all the viruses detected. Five patients (2.5%) had two viruses detected in NPA: RSV + bocavirus (1), RSV + influenza A (1), RSV + HRV (1), HRV + bocavirus (1), and HRV + influenza B (1). Of those admitted patients, 119 NPA samples were sent for bacterial culture and 44 patients had a positive culture (37%).

Risk factors for admission

Virus detection was not associated with hospitalization [Table 2]. In Univariate analysis, factors possibly associated with the need for admission were young age, female gender, Malay ethnicity, attending nursery, diagnosis of pneumonia and not being breastfed [Table 1]. Binary logistic regression identified that female gender, attending nursery, and not being breastfed were independent risk factors for hospitalization [Table 3].

Clinical responses to viral infections

The following symptoms were not associated with virus infection: fever ($P = 0.45$, OR 0.79 [95% CI 0.44, 3.42]), rhinitis ($P = 0.08$, OR 1.87 [95% CI 0.93, 3.75]), shortness of breath (0.65, OR 0.84 [95% CI 0.46, 1.52]), presence of wheezing ($P = 0.82$, OR 1.06 [95% CI 0.59, 1.91]), and diarrhea ($P = 0.35$, OR 2.06 [95% CI 0.52, 8.19]).

Only 2 cases of apnea were admitted during this study and RSV and rhinovirus accounted for these two cases. There was a significant association between the symptom of vomiting and virus detection ($P < 0.001$, OR 4.67 [95% CI 1.94, 11.24]). All the six children who had life-threatening pneumonia had viruses detected in their NPA (influenza [$n = 1$], RSV [$n = 1$], rhinovirus [$n = 2$], rhinovirus + RSV [$n = 1$], and bocavirus [$n = 1$]),

Table 2: Odds ratio of admission for nasopharyngeal aspirates positive viral cases

Virus	Positive and admitted/total positive (%)	P	OR	95% CI
Any positive	108/181	0.157	0.865	0.708-1.056
RSV	30/53 (56.6)	0.112	0.824	0.635-1.068
Rhinovirus	23/33 (70.0)	0.579	1.078	0.838-1.386
Parainfluenza	7/13 (53.8)	0.377§	0.812	0.486-1.357
Influenza	5/7 (71.4)	1.000§	1.094	0.677-1.768
Bocavirus	3/5 (60.0)	1.000§	0.914	0.914-1.883
hMPV	1/2 (50.0)	1.00§	0.762	0.190-3.056
Adenovirus	0/1 (0.0)	0.330§	-	-

§Fisher's exact test. RSV: Respiratory syncytial virus, hMPV: Human metapneumovirus, OR: Odds ratio, CI: Confidence interval

Table 3: Binary logistic regression analysis of factors that were significantly associated with admission to hospital

	OR	95% CI	P
Female	2.10	1.047-4.202	0.037
Breastfeeding	0.397	0.169-0.933	0.034
Attending nursery	2.087	1.119-3.891	0.021

OR: Odds ratio, CI: Confidence interval

$P = 0.05$ (OR 8.37 [95% CI 0.96, 255.2]). None of the children were intubated for their infection and there were no deaths.

Clinical responses to specific viruses

Children ≤6 months were not more likely to be infected with RSV ($P = 0.25$, OR 1.49 [95% CI 0.79, 2.82]). Both HRV detection ($P = 0.16$, OR = 2.03 [95% CI 0.83, 4.96]) and RSV detection ($P = 0.40$, OR = 0.75 [95% CI 0.39, 1.45]) were not associated with current wheezing. However, RSV detection was significantly associated with a previous history of wheeze ($P = 0.03$, OR 2.05 [95% CI 1.06, 4.00]). This association was not seen with HRV ($P = 0.85$, OR 1.17 [95% CI 0.54, 2.0].

Discussion

In this prospective study, half of the young children presenting to the PED with ALRI were positive for a respiratory virus, but there was no significant association between virus detection and hospitalization. However, all six severely ill children had viruses detected in their NPA. We found three significant clinical factors associated with admission: female sex, nursery attendance, and lack of breastfeeding. RSV, and not HRV, was detected more frequently in children with a previous history of wheezing. Symptom of vomiting was significantly associated with viral detection.

This study was conducted in a tertiary hospital, located in an urban city, with a high attendance of children presenting with respiratory infections, and only young children with ALRI were included. All samples were NPAs, the optimal specimen for viral detection.[6,7] Half of the samples (50.7%) were positive for a virus and 2.5% had mixed viral infections. A retrospective study from the Netherlands, done in the accident and emergency department during two winter seasons, showed that 82% of 274 samples were positive for a single virus and 23% had mixed viral infections.[5] In another study from France about childhood upper and lower respiratory tract infections, 89% of samples were positive.[4] A possible reason for the extremely high positivity rate in the study from the Netherlands was the sampling period, when viral infections would be at its peak. In a tropical climate like Malaysia, it was shown that RSV had its peak season from September to December but generally viruses are prevalent throughout the year.[8,9] In a study in Beijing, China, which included both inpatients and outpatients, using reverse transcriptase PCR to detect viruses, 61.7% of patients were positive for a virus, a rate similar to ours.[10] RSV was the most common virus detected in those who were admitted while influenza was most common in those who were discharged, and being positive for any virus was not associated with admission (69% in those admitted versus 54% in those discharged).[10] In another inpatient-based study, conducted in the Philippines, involving 819 children admitted with severe pneumonia and using PCR to detect viruses, the positivity rate was also 61% with HRV and RSV being the most common viruses detected.[11] This study had a low mixed infection rate of 8%,[11] compared to other studies which found mixed viral infection rates of 14%–40%.[3,12,13] In

a review of published studies, viruses were found in 43%–67% of children with community-acquired pneumonia in children, although the detection rate will be affected by many factors including type and extent of molecular assay used, season, sample population, indications for testing, and methods of sample collection and processing.[14,15]

The most common viruses detected in our study were RSV, HRV, and parainfluenza virus, similar to the other studies, both in Asia and Europe.[5,10,11] RSV but not rhinovirus was associated with previous history of wheezing, but neither HRV nor RSV was significantly associated with current wheezing. This finding differed from that in the Netherlands, where prior treatment with steroids and salbutamol was associated with HRV.[5] Both HRV and RSV were reported to be associated with increased risk for future wheezing. RSV is more likely an "inducer" by its neuroimmune effect on the airways and not via allergic sensitization whereas HRV is a "trigger" inducing release of chemokines and cytokines that triggers the allergic pathway in a child with a predisposition to asthma.[16] As for severity of disease, while in this study neither RSV nor any other virus was associated with severity of illness, all children who had severe respiratory compromise were virus positive. In the Netherlands, HRV was associated with severe disease while RSV was inversely associated with severity of disease.[5] HRV-C is known to be associated with lower respiratory tract infections while HRV-A and B is associated with upper respiratory tract infections.[17] We did not include the HRV in this study. However, one patient who was HRV positive had a severe ALRI requiring noninvasive ventilation support. There was evidence that HRV might not be all benign.[5]

The role of mixed viral infections could not be evaluated in this study due to the small number of positive samples. Nonetheless, globally, its impact on ALRIs was also not clear.[18] This is due to the high sensitivity of PCR, which may detect asymptomatic infections or low levels of virus from recent, resolved infections, hence resulting in over detection of "innocent" pathogens, especially rhinovirus.[19] Nevertheless, some studies showed an association between mixed viral infections with increased severity of illness.[10,12]

The other important finding of our study was the three clinical factors significantly associated with the need for admission: female gender, nursery care, and lack of breastfeeding. Other factors such as age and exposure to ETS were not significant. The protective effect of breastfeeding against ALRI confirmed findings in other studies.[2,20] Care outside the home, if more than 6 children are in attendance, was shown to be associated with hospitalization for an ALRI.[21]

Finally, in this study, children with a clinical presentation of vomiting were more likely to have viruses detected in their NPA. Vomiting is a known sign of an infection in a child and is not specific to the gastrointestinal system.[22]

The main strength of this study is that it is a prospective study and looks at the impact of viruses in the Emergency Department of a developing country.

Limitations to this study included the small sample size with only 200 patients recruited as patients who attended during the weekends were excluded from the study. We recognize the possible impact of bacterial–viral infections on increasing severity of illness; however, we cannot report on this as only children who were admitted had bacterial cultures done. This study was also done in a tertiary hospital, and hence, the results may not be extrapolated to the rest of Malaysia.

CONCLUSIONS

Detection of viruses in children presenting to the PED was not associated with hospitalization for an ALRI. About half of the children presenting to PED were positive for a respiratory virus. All children who were severely ill, requiring noninvasive ventilation, had viruses detected in their NPA. Three clinical factors significantly associated with the need for admission were being female, attending nursery, and lack of breastfeeding. RSV but not HRV was detected more frequently in children with a previous history of wheeze.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Tiewsoh K, Lodha R, Pandey RM, Broor S, Kalaivani M, Kabra SK. Factors determining the outcome of children hospitalized with severe pneumonia. BMC Pediatr 2009;9:15.
2. Nathan AM, Rani F, Lee RJ, Zaki R, Westerhout C, Sam IC, *et al.* Clinical risk factors for life-threatening lower respiratory tract infections in children: A retrospective study in an urban city in Malaysia. PLoS One 2014;9:e111162.
3. García-García ML, Calvo C, Pozo F, Villadangos PA, Pérez-Breña P, Casas I. Spectrum of respiratory viruses in children with community-acquired pneumonia. Pediatr Infect Dis J 2012;31:808-13.
4. Mengelle C, Mansuy JM, Pierre A, Claudet I, Grouteau E, Micheau P, *et al.* The use of a multiplex real-time PCR assay for diagnosing acute respiratory viral infections in children attending an emergency unit. J Clin Virol 2014;61:411-7.
5. Gooskens J, van der Ploeg V, Sukhai RN, Vossen AC, Claas EC, Kroes AC. Clinical evaluation of viral acute respiratory tract infections in children presenting to the emergency department of a tertiary referral hospital in the Netherlands. BMC Pediatr 2014;14:297.
6. Wurzel DF, Marchant JM, Clark JE, Mackay IM, Wang CY, *et al.* Respiratory virus detection in nasopharyngeal aspirate versus bronchoalveolar lavage is dependent on virus type in children with chronic respiratory symptoms. J Clin Virol 2013;58:683-8.
7. Sung RY, Chan PK, Choi KC, Yeung AC, Li AM, Tang JW, *et al.* Comparative study of nasopharyngeal aspirate and nasal swab

specimens for diagnosis of acute viral respiratory infection. J Clin Microbiol 2008;46:3073-6.

8. Chan PW, Chew FT, Tan TN, Chua KB, Hooi PS. Seasonal variation in respiratory syncytial virus chest infection in the tropics. Pediatr Pulmonol 2002;34:47-51.

9. Khor CS, Sam IC, Hooi PS, Quek KF, Chan YF. Epidemiology and seasonality of respiratory viral infections in hospitalized children in Kuala Lumpur, Malaysia: A retrospective study of 27 years. BMC Pediatr 2012;12:32.

10. Liu CY, Xiao Y, Xie ZD, Ren LL, Hu YH, Yao Y, *et al.* Viral etiology of acute respiratory tract infection among pediatric inpatients and outpatients from 2010 to 2012 in Beijing, China. Zhonghua Er Ke Za Zhi 2013;51:255-9.

11. Suzuki A, Lupisan S, Furuse Y, Fuji N, Saito M, Tamaki R, *et al.* Respiratory viruses from hospitalized children with severe pneumonia in the Philippines. BMC Infect Dis 2012;12:267.

12. Cilla G, Oñate E, Perez-Yarza EG, Montes M, Vicente D, Perez-Trallero E. Viruses in community-acquired pneumonia in children aged less than 3 years old: High rate of viral coinfection. J Med Virol 2008;80:1843-9.

13. Laurent C, Dugue AE, Brouard J, Nimal D, Dina J, *et al.* Viral epidemiology and severity of respiratory infections in infants in 2009: A prospective study. Pediatr Infect Dis J 2012;31:827-31.

14. Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. Lancet 2011;377:1264-75.

15. Zhang G, Hu Y, Wang H, Zhang L, Bao Y, Zhou X. High incidence of multiple viral infections identified in upper respiratory tract infected children under three years of age in Shanghai, China. PLoS One 2012;7:e44568.

16. Rossi GA, Colin AA. Infantile respiratory syncytial virus and human rhinovirus infections: Respective role in inception and persistence of wheezing. Eur Respir J 2015;45:774-89.

17. Martin EK, Kuypers J, Chu HY, Lacombe K, Qin X, Strelitz B, *et al.* Molecular epidemiology of human rhinovirus infections in the pediatric emergency department. J Clin Virol 2015;62:25-31.

18. Debiaggi M, Canducci F, Ceresola ER, Clementi M. The role of infections and coinfections with newly identified and emerging respiratory viruses in children. Virol J 2012;9:247.

19. van Benten I, Koopman L, Niesters B, Hop W, van Middelkoop B, de Waal L, *et al.* Predominance of rhinovirus in the nose of symptomatic and asymptomatic infants. Pediatr Allergy Immunol 2003;14:363-70.

20. Duijts L, Jaddoe VW, Hofman A, Moll HA. Prolonged and exclusive breastfeeding reduces the risk of infectious diseases in infancy. Pediatrics 2010;126:e18-25.

21. Anderson LJ, Parker RA, Strikas RA, Farrar JA, Gangarosa EJ, Keyserling HL, *et al.* Day-care center attendance and hospitalization for lower respiratory tract illness. Pediatrics 1988;82:300-8.

22. Sam IC, Abdul-Murad A, Karunakaran R, Rampal S, Chan YF, Nathan AM, *et al.* Clinical features of Malaysian children hospitalized with community-acquired seasonal influenza. Int J Infect Dis 2010;14 Suppl 3:e36-40.

Pediatric Respirology and Critical Care Medicine on Web

http://www.journalonweb.com/prcm

Pediatric Respirology and Critical Care Medicine now accepts articles electronically. It is easy, convenient and fast. Check following steps:

1 Registration

- Register from http://www.journalonweb.com/prcm as a new author (Signup as author)
- Two-step self-explanatory process

2 New article submission

- Prepare your files (Article file, First page file and Images, if any)
- Login into your area
- Click on 'Submit a new article' under 'New Article'
- Follow the steps (three steps for article without images and five for with images)
- On successful submission you will receive an acknowledgement quoting the manuscript numbers

3 Tracking the progress

- Click on 'In Review Article' under 'Submitted Articles'
- The table gives status of the article and its due date to move to next phase
- More details can be obtained by clicking on the Manuscript ID
- Comments sent by the editor and referee will be available from these pages

4 Submitting a revised article

- Click on 'Article for Revision' under 'Submitted Articles'
- Click on 'Revise'
- From the first window, you can modify Article Title, Article Type
- First Page file and Images could be modified from second and third window, respectively
- The fourth step is uploading the revised article file.
- Include the referees' comments along with the point to point clarifications at the beginning of the revised article file.
- Do not include authors' name in the article file.
- Upload the revised article file against New Article File - Browse, choose your file and then click "Upload" OR Click "Finish"
- On completion of revision process you will be able to check the latest file uploaded from Article Cycle (In Review Articles-> Click on manuscript ID -> Latest file will have a number with 'R')

Facilities

- Submission of new articles with images
- Submission of revised articles
- Checking of proofs
- Track the progress of article in review process

Advantages

- Any-time, any-where access
- Faster review
- Cost saving on postage
- No need for hard-copy submission (except on acceptance images should be sent)
- Ability to track the progress
- Ease of contacting the journal

Requirements for usage

- Computer and internet connection
- Web-browser (preferably newer versions - IE 5.0 or NS 4.7 and above)
- Cookies and javascript to be enabled in web-browser

Online submission checklist

- First Page File (text/rtf/doc/pdf file) with title page, covering letter, acknowledge-ment, etc.
- Article File (text/rtf/doc/pdf file) - text of the article, beginning from Title, Abstract till References (including tables). File size limit 1 MB. Do not include images in this file.
- Images (jpeg): Submit good quality colour images. Each image should be less than 4096 kb (4 MB) in size.

Help

- Check Frequently Asked Questions (FAQs) on the site
- In case of any difficulty contact the editor

There's No Place Like Home.

Synagis can help keep babies there.

Severe RSV disease can threaten a baby's welcome home. Synagis significantly decreases RSV-related hospitalization rates in high-risk infants.[1] Synagis Solution for Injection is a line extension of the original Synagis brand. In fact, the new formulation uses the same, active ingredient that physicians, nurses, and pharmacists have come to trust for the last 15 years.

Compared to the lyophilised formulation of Synagis, the new liquid formulation is ready-to-use, eliminating the need for reconstitution and simplifying the preparation process.

Now Available in New Liquid Formulation.

Synagis® 100 mg/ml
Palivizumab
50 mg/0.5 ml
Solution for Injection

Synagis® 100 mg/ml
Palivizumab
100 mg/1 ml
Solution for Injection

Synagis solution for injection abbreviated prescribing information

Presentation: 50mg/0.5ml or 100mg/1ml solution for injection. **Indications:** Prevention of serious lower respiratory tract disease requiring hospitalization caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease: 1) Children born at 35 weeks of gestation or less and less than 6 months of age at the onset of RSV season; 2) Children less than 2 years of age and requiring treatment for bronchopulmonary dysplasia within the last 6 months; 3) Children less than 2 years of age and with haemodynamically significant congenital heart disease. **Dosage:** 15mg/kg once a month IM during anticipated periods of RSV risk in the community. **Contraindications:** Known hypersensitivity to palivizumab or any of its ingredients (histidine, glycine and water for injections), or other humanized monoclonal antibodies. **Precautions:** Allergic reactions; Patients with thrombocytopenia or any coagulation disorder. **Interactions:** No formal drug-drug interaction studies were conducted. Immune-based RSV diagnostic tests or viral culture assays may be interfered, causing false-negative RSV diagnostic test. **Undesirable effects:** Fever, rash and injection site reaction. **Full local prescribing information is available upon request. API.HK.SYL.0615**

1) The IMpact-RSV Study Group. Palivizumab, a humanised respiratory syncytial virus monoclonal antibody, reduces hospitalisation from respiratory syncytial virus infection in high-risk infants. *Pediatrics*. 1998; 102: 531-537

SYNAGIS®
PALIVIZUMAB

abbvie

Abbvie Limited
Unit 2405-08, 24/F, AIA Tower
183 Electric Road, North Point, Hong Kong
T +852 2559 5888   F +852 2559 6910

PP-SYN-HK-0002

Frisolac 美素力

FRISOLAC® Gold Comfort

Relief minor digestive discomforts: Regurgitation, Hard Stools and Colic for infants from 0 to 12 months

✓ **Contains natural cold soluble carob bean gum**
- Carob bean gum in the formula is changed from hot soluble to cold soluble
- Effectiveness of new enhanced FRISOLAC® Gold Comfort with reduced levels of carob bean gum (CGB) (0.33 g/ 100 mL)

  - Significant decline in reflux episodes (total number of refluxes per day)
  - Significant decline in oesophageal exposure to acid (Boix Ochoa Score)

New formulation
0.33 g/100 mL
cold soluble CBG

Old formulation
0.45 g/100 mL
hot soluble CBG

% decrease

*67.7% *73.3%

28.5% 19.8%

- Total refluxes
- Boix Ochoa Score (acid exposure)

* $P<0.05$ for decrease between baseline and follow up

A randomized, partly double blind clinical trial conducted in the University Hospital "St. Marine" Varna, Bulgaria
Fifty-six eligible infants (1-6 mo old) were randomly allocated to receive for two weeks a formula with either 0.33 g/100 mL or 0.45 g/100 mL of cold soluble CBG galactomannans respectively or a formula with 0.45 g/100 mL of hot soluble CBG galactomannans.
Reference: Georgieva M, Manios Y, Rasheva N, Pancheva R, Dimitrova E, Schaafsma A. Effects of carob-bean gum thickened formulas on infants' reflux and tolerance indices, *World J Clin Pediatr*, 2016 February 8; 5(1): 118-127.

✓ **Newly added partially hydrolysed whey proteins**
- Approximately 25% of total proteins are partially hydrolyzed (40 - 45% whey protein) which support digestion

✓ **Balanced nutrition†**
- Provide important nutrients that support healthy growth and development, including DHA, AA, nucleotides, selenium, taurine, choline and more

† Balanced nutrition for infants from 0-6 months. From 6 months onwards, infants need complementary foods to achieve balanced diet.

CAROB BEAN GUM
DHA

Frisolac
GOLD 全装
Comfort

ERS EUROPEAN RESPIRATORY SOCIETY

every breath counts

APPS
ASIAN PAEDIATRIC PULMONOLOGY SOCIETY

HERMES
Harmonised Education in Respiratory Medicine for European Specialists

A chance to obtain an international qualification in paediatric respiratory medicine

The second joint ERS/APPS examination will be held on 27 October 2017 in Bengaluru, India. There will be two parts:

- Part I: ERS HERMES^ Examination in Paediatric Respiratory Medicine – 3 hours
- Part II: APPS diplomate examination on Asian Paediatric Respiratory Medicine – 0.5 hour

Candidates who pass part I will be awarded the European Diploma in Paediatric Respiratory Medicine by ERS.
Candidates who also pass part II will be awarded Diplomate of APPS.

There will be one day pre-exam crash course to be held on 26 October 2017 in Bengaluru, India.

Fees:

- Pre-exam crash course: USD 100
- Examination: USD 600

Application:

- Candidate must send in (i) application form; (ii) support letter from council members or office bearers of APPS; (iii) payment receipt to apps.medisociety@gmail.com
- Deadline of Application: 15 August 2017

Eligibility Criteria:

- Specialists in paediatric respiratory medicine recognised in their respective home countries and endorsed by council members or office bearers of APPS.

Useful Links:

- Syllabus – http://hermes.ersnet.org/images/paediasyllabus_HERMES_Breathe_Paediatric_Syllabus.pdf
- Blueprint – http://hermes.ersnet.org/images/PRM%20Blueprint_revised.pdf
- Handbook – http://www.ersbookshop.com/ers-handbook-of-paediatric-respiratory-medicine-119-p.asp
- Sample Test – http://www.ers-education.org/MOS_R1/MosPub/HERMES_Test/index.html
- Practical Tips – http://hermes.ersnet.org/images/getting%20ready.pdf

Enquiry:

Please contact Ms. Melissa Leung by email:
apps.medisociety@gmail.com

^HERMES – Harmonising Education in Respiratory Medicine for European Specialists

香港兒童呼吸及過敏學會
Hong Kong Society of
PAEDIATRIC RESPIROLOGY AND ALLERGY

9th Cross-Strait Paediatric Respirology Congress
第九屆海峽兩岸兒科呼吸會議

cum
暨

20th HKSPRA Annual Scientific Meeting
第廿屆香港兒童呼吸及過敏學會周年學術會議

21 – 22 October 2017
Cordis Hong Kong

Mark Your Diary!

Offsite Courses
• 17 – 20 October 2017: Comprehensive Introduction Course to Orofacial Myofunctional Therapy
• 20 October 2017: Lung Function Course
• 24 – 27 October 2017: Advanced Breathing Re-education Course for Myofunctional Therapy

Onsite Workshops
• Accredited Training of Heated Humidified High Flow in Infants and Children
• Interventional Pulmonology in Paediatrics: A Beginner Class
• Skin and Allergy

Plenary Lectures and Symposia
• Allergy
• Critical Care
• Infection
• Interventional Pulmonology
• Lung Function
• Respirology
• Skin
• Sleep

Confirmed Speakers
Dr. Victor Abdullah, *United Christian Hospital*
Ms. Katherine Cheung, *Kwong Wah Hospital*
Professor Zen-kong Dai, *Kaohsiung*
Ms. Robin Glass, *Washington*
Dr. Mark Goh, *Singapore*
Professor Christian Guilleminault, *California*
Professor Ellis Hon, *The Chinese University of Hong Kong*
Professor Kai-sheng Hsieh, *Kaohsiung*
Ms. Marcella King, *Kwong Wah Hospital*
Dr. Carrie Kwok, *Kwong Wah Hospital*
Professor Shen-hao Lai, *Taipei*
Professor Ting-fan Leung, *The Chinese University of Hong Kong*
Professor Albert Li, *The Chinese University of Hong Kong*
Professor Ching-yuang Lin, *Taichung*
Dr. David Luk, *United Christian Hospital*
Mr. Patrick McKeown, *Dublin*
Professor Chen Meng, *Jinan*
Ms. Joy Moeller, *California*
Professor Ashkan Moslehi, *Shiraz*
Dr. Daniel Ng, *Kwong Wah Hospital*
Dr. Andreas Schibler, *Brisbane*
Professor Wen-jue Soong, *Taipei*
Ms. Ching-yee To, *Kwong Wah Hospital*
Dr. Liam Welsh, *Melbourne*
Professor Gary Wong, *The Chinese University of Hong Kong*
Dr. Kin-sun Wong, *Taipei*
Professor Zhi-fei Xu, *Beijing*
Ms. Anna Ydreos, *Melbourne*

Academic Accreditations
CME, CNE and CPD points will be applied for the meeting.

Offsite Courses Co-organizers
• Academy of Orofacial Myofunctional Therapy
• Asian Paediatric Pulmonology Society
• Department of Paediatrics, Kwong Wah Hospital
• Department of Physiotherapy, Kwong Wah Hospital

Supporting Organizations
• Asian Paediatric Pulmonology Society
• Chinese Paediatric Interventional Pulmonology Society
• Hong Kong College of Paediatricians
• Hong Kong Institute of Allergy
• Hong Kong Medical Association
• Hong Kong Neonatal Society
• Hong Kong Paediatric Nurses Association
• Hong Kong Society of Sleep Medicine

www.hkspra.org

Enquiry:
International Conference Consultants Limited (ICC)
Tel: (852) 2559 9973
Email: hkspra2017@icc.com.hk

NUTRICIA

Aptamil 3
白金版

One-Step-Ahead Science
to build babies' future health

ENP™ Formula

scGOS:lcFOS 9:1

SN2 Palmitic acid

LCPUFAs

NUTRICIA's 40 years of research
in natural nutrition

respicOn 2017

29th Annual National Conference of IAP Respiratory Chapter
3rd APPS (Asian Pediatric Pulmonology Society) Meeting

October 2017 will take your breath away! We are delighted to announce RESPICON 2017 - the 29th Annual IAP (Indian Academy of Pediatrics) Respiratory Conference in association with the 3rd APPS (Asian Pediatric Pulmonology Society) meet to be held at Bengaluru, India from the 26th to 29th October, 2017.

With a confluence of international speakers, interesting scientific sessions & expert interactions, the RESPICON 2017 conference will bring together the best minds & lungs. There is a lot to imbibe from experienced General Practioners, Pediatric Pulmonologists & Allied Health Care Professionals.

Looking forward to your participation. We promise that the conference will be *breath taking!*

Registrations
www.respicon2017.com

Enquiries
info@respicon2017.com

pHERMES Exams	Scientific Workshops
26 & 27 Oct 2017	26 & 27 Oct 2017

Main Conference
28 & 29 Oct 2017

Breathe Baccha Breathe

Programs / schedules may be subject to change